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INTRODUCTION 
The process of growth and development has long 
occupied the human intellect, ranging from scientists 
pondering the basic physiological mechanisms controlling 
growth, to animal producers hoping to improve growth of 
their stock, to future athletes wondering to what extent 
they are going to grow. 
Understanding the basic concepts that control growth 
is generally limited to the techniques which are currently 
available to measure biological processes. For example, 
the development of radioimmunoassay (RIA) for sensitive 
and precise measurement of plasma hormone concentrations 
made major contributions towards understanding growth. 
However, there were still many inconsistencies when 
correlating a certain event in the growth/developmental 
process with existing parameters of the hormone in plasma. 
With recent rapid advances in recombinant DNA 
technology, precise, quantitative and sensitive 
measurements of the level of expression of a specific gene 
can now be measured. This is advantageous as growth 
events can occur in a tissue independent of and 
nondetectable by any changes in plasma hormones. For 
example, growth hormone (GH) and estrogen (Eg) stimulate 
growth of steers to an equivalent degree. However, the 
concentrations of insulin-like growth factor-1 (I6F-1) in 
plasma, a hormone thought to be primarily responsible for 
normal postnatal growth, are not equally affected by these 
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two treatments (1). Therefore, the growth response to 
these treatments could be mediated through expression of 
the IGF-1 gene in different tissues. One tissue could be 
stimulated to synthesize and release IGF-1 into plasma, 
while the other tissue might not possess the capabilities 
to release peptides and retain the IGF-1 it produces. 
Often, only by detecting altered expression of a specific 
gene and/or genes can the stimulus for a biological event 
be observed. As with RIA, this has led to many advances 
in understanding growth concepts which previously could 
only be speculated. 
It is important to note that recombinant DNA 
technology is an important extension to, and not a 
replacement for, sound basic physiological research. 
Therefore, it was the objective of this work to utilize 
recombinant DNA technology as an aid to answer some 
anomalies that exist between plasma growth regulatory 
hormone concentrations and actual observed growth response 
in cattle. This was accomplished by determining the 
influence GH, Eg, thyroxine (T4), and triiodothyronine 
(T3) exert on IGF-1 messenger ribonucleic acid (mRNA) 
concentrations in liver and skeletal muscle of cattle, as 
well as plasma concentrations of IGF-1. 
3 
REVIEW OF THE LITERATURE 
The IGF-1 Gene 
There is one copy of the IGF-1 gene per haploid 
genome (2). Therefore, the multiple IGF-1 mRNA species 
observed and reported to date are presumably due to 
alternative processing of the IGF-1 gene. Depicted in 
Figure 1 is structure of the human IGF-1 mRNA. Cloning 
and sequencing analysis has revealed that there are 6 
possible different IGF-1 mRNAs. IGF-la and IGF-lb are 
mRNA transcripts which have identical coding sequences for 
the B, C, A, D, and first 16 residues of the E domain, but 
they then diverge in sequence to specify E domains with 
different 3' carboxy terminal extensions (3). IGF-la mRNA 
has a 57 nucleotide E peptide carboxy terminus coding 
region, along with 284 nucleotide 3' untranslated region, 
all originating from exon 5. The IGF-lb mRNA has a 183 
nucleotide E peptide carboxy terminus coding region, along 
with a 329 nucleotide 3' untranslated region, all 
originating from exon 4. The function of the E peptides, 
which are rapidly cleaved from the preproprotein to form 
the mature 70 amino acid IGF-1 peptide, is not known. 
Studies in the rat have shown that IGF-lb is present at 
low abundance (approximately 5%) relative to IGF-la in all 
Figure 1. Structure of the human IGP-1 mRNA. Black descending arrows 
depict exon boundaries. Solid black bars at right and left 
ends of gene represent untranslated nucleotide sequences. 
Numbers represent number of nucleotides. The letters P, A, 
B, C, D, and E followed by a number represent the 
corresponding region of the preproprotexn, and the number of 
nucleotides which code for that region. The 210 nucleotides 
which code for the mature 70 amino acid IGP-1 peptide are 
indicated 
1 Exon 4 
Eb 183 
329 3'UTR 
Exon 1 I Exon 2 I I Exon 3 i Exon 5 
>238 5'< 
1 P 63 P 81 1 B 76 B 11 C 36 A 63 0 24 1 E 48 Ea 57 
I Î 
284 3* UTR Ul 
Matur* IGF-1 Peptide 
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tissues except the liver, where it is approximately 10% 
the relative abundance of IGF-la (4). Both IGF-la and 
bare coordinately increased by GH in all tissues except 
the liver, where the increase in IGF-lb mRNA was 
approximately 3 times greater than the increase in IGF-la 
mRNA levels (4). 
IGF-IA, IGF-IB, and IGF-IC are IGF-1 mRNAs that 
differ in their 5' sequences (5). The function of the 
different 5' ends is unknown. Studies in the rat have 
shown that heart, muscle, and brain contain only type C. 
The liver contains the A, B, and C forms, while the 
kidney, lung, stomach, and testes contain only the A and C 
forms. In all of these tissues class C is the most 
predominant form, approximately 4 fold greater than class 
A in the liver and kidney. All three classes are GH 
responsive, albeit with slightly different sensitivities 
(6). In the rat, all three types have been found in 
association with both IGF-la and IGF-lb mRNAs (7). 
Therefore, with two alternative 3' ends and three 
alternative 5' ends, there are six possible IGF-1 mRNAs. 
In addition to the complexity of IGF-1 mRNAs 
suggested by the sequence analysis of cDNAs, Northern 
analysis has yielded IGF-1 mRNA's of approximately 8, 5, 
2, and .8 Kb in length in samples of human (8) and rat (9) 
liver RNA. Recent studies in rats have shown that the 
size difference is primarily due to variation in the 3' 
UTRs (10). IGF-la, b. A, B, and C mRNA forms migrate at 
each of the observed sizes (7). It is important to note 
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Table 1. Factors controlling IGF-1 mRNA expression 
Factor® Response' 
u Tissue/ 
" Cell Type Species Ref 
GH ++ Liver, lung, 
heart, kidney, 
thymus, spleen, 
rib growth plate, 
mammary tissue 
Hypox rat, 
Mature female 
Rat (Intact), 
Salmon 
h'iï-
GH (phys) ne Liver, kidney, 
spleen, lung, 
heart,pancreas 
Mature male 
mice (Intact) 
16 
GH ne Differentiating 
muscle C2 cells, 
skeletal muscle 
Mouse, 
Finishing pigs 
17,18 
^2 ++ Uterus, ovary, rat osteoblasts 
Immature 
hypox rat 
19,20, 
21 
GH+Eg — Uterus, liver Immature 
hypox rat 
20 
PRL ++ Liver Hypox rat 22 
FSH, LH ++ Testes Immature 
hypox rat 
23 
T3 ne Liver Hypox rat 24 
Dexameth-
azone 
— —  Liver, tibia, 
lung, kidney rat 
25 
PTH ++ Fetal rat 
osteoblast cells 
26 
Age ++ Liver, heart, 
kidney 
Intact rat 6 
Age — —  Skeletal muscle, 
stomach 
Intact rat 6 
Injury ++ Regenerating 
skeletal muscle 
Intact rat 27 
When factor is a hormone, dosage was 
pharmacological, unless specified with (phys), which 
signifies a physiological dose. 
^++ = stimulative effect; — = negative effect; ne = 
no effect. 
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that although there are many forms of the IGF-1 mRNA, all 
forms still code for the identical IGF-1 prepropeptide. 
Factors Affecting IGF-1 mRNA Expression 
With the availability of several IGF-1 cDNAs, many 
different studies of factors affecting IGF-1 mRNA have 
been undertaken. A summary of these studies is shown in 
Table 1. 
Many studies have investigated the effects of GH on 
IGF-1 mRNA expression in a multitude of tissues 
(9,11,12,13,14,16). The responsiveness of IGF-1 mRNA to 
GH in many tissues is lost when physiological doses are 
administered to intact animals (16,18). While GH was 
originally thought to be the primary regulator of IGF-1 
mRNA expression, the importance of other growth regulatory 
hormones soon became evident. Eg, follicle stimulating 
hormone (FSH), luteinizing hormone (LH), parathyroid 
hormone (PTH), and prolactin (PRL) stimulate IGF-1 gene 
expression in specific target tissue, independent of GH 
(19,20,21,22,23,26). GH actually antagonizes the Eg 
stimulation of uterus IGF-1 expression (20). The 
decreasing developmental expression of IGF-1 mRNA in rat 
skeletal muscle (6) could reflect the decreasing activity 
or number of satellite cells within maturing muscle, while 
an increase in IGF-1 expression in regenerating muscle 
could reflect the stimulation of quiescent satellite cells 
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(see below). 
It is apparent that IGF-1 mRNA expression is an 
important mediator of the mitogenic response stimulated by 
a myriad of hormones, rather than just a mediator of GH 
action. 
Metabolic Effects of IGF-1 
Autocrine/paracrine versus endocrine effects of IGF-1 
IGF-1 has been implicated in control of postnatal 
growth ever since the classical work of Salmon and 
Daughaday (28), in which they discovered a "sulfation 
factor". This led to the development of the original 
somadamedin hypothesis, which is as follows: pituitary 
derived GH is a regulator of serum concentrations of IGF-1 
(29,30), a 70 amino acid polypeptide produced primarily in 
the liver (31), and acting in an endocrine fashion to 
stimulate normal skeletal growth (32). Support for this 
theory includes studies demonstrating that recombinantly 
derived IGF-1 stimulates growth of rats (33,34,35), and 
reports indicating the extremely high correlation between 
plasma IGF-1 concentrations and body weight in poodles 
(36) and cattle (37). 
Recent evidence, however, has refuted the original 
hypothesis, suggesting an autocrine/paracrine role for 
IGF-1. Strong support for IGF-1 as an autocrine/paracrine 
growth factor was generated by experiments showing 
multihormonal regulation of IGF-1 mRNA in a variety of 
tissues/cells (see above), as well as studies 
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demonstrating the capability of several cell lines to 
produce and secrete both IGF-1 and its binding proteins 
into media in vitro (38). The most compelling support for 
IGF-1 acting as an autocrine/paracrine growth factor in 
vivo was the demonstration that in an isolated rat 
hindlimb preparation, the growth stimulation, relative to 
the contralateral limb, caused by infusion of GH could be 
blocked by antiserum against IGF-1 (39). However, the 
importance, for somatic growth, of IGF-1 produced by the 
liver and acting in an endocrine manner versus IGF-l 
produced by target tissues and acting in an 
autocrine/paracrine manner remains to be resolved. 
Importance of IGF-1 and other growth factors for skeletal 
muscle growth 
Prenatal skeletal muscle growth is generally 
characterized by two phases, the proliferative stage and 
the differentiation stage (40). The proliferative stage 
is characterized by a proliferation of mononucleated 
presumptive myoblasts, while the differentiation stage is 
marked by a differentiation of the presumptive myoblasts 
into myoblasts, after which groups of these myoblasts fuse 
to form multinucleated myotubes. These myotubes then 
acquire myofibrils to become muscle fibers. 
Both IGF-1 and IGF-2 have been shown to enhance 
proliferation, differentiation, and nutrient uptake, while 
depressing proteolysis of myoblasts. The importance of 
IGF-1 and IGF-2 for differentiation was demonstrated in a 
study using a myogenic C2 cell line (17). These myoblasts 
form contracting myotubes 96-120 hours after triggering 
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the differentiation program. The synthesis of IGF-1 mRNA, 
peptide and binding protein by myoblasts was low during 
proliferation. Expression of IGF-1 mRNA peaked 
transiently 46-72h after the triggering of 
differentiation, and was 6-10 fold higher than levels 
observed in proliferating myoblasts. The production of 
IGF-1 binding protein is induced 30 fold 16 h after 
triggering differentiation. The relative abundance of 
IGF-2 mRNA at 72 h after triggering differentiation was 15 
fold higher than levels of IGF-1 mRNA. 
Other growth factors have also been implicated in the 
regulation of myoblast development. Fiberblast growth 
factor (FGF) is highly mitogenic in myoblasts (41). FGF, 
transforming growth factor-beta (T6F-/9), and the oncogenes 
src and myc have been shown to inhibit differentiation 
(42). Epidermal growth factor (EGF) does not appear to 
have any effect on myoblasts (43). 
Since the number of muscle fibers is fixed at birth 
or soon after, postnatal growth of muscle in young animals 
is a result of muscle fiber hypertrophy (44). Studies in 
cattle have shown that this postnatal hypertrophy of 
skeletal muscle fibers is characterized by two general 
phases (45). The first phase is an increase in 
cellularity and cell size, while the second phase is 
primarily an increase in cell size. 
The first phase of postnatal growth is a combination 
of increasing cellularity (number of nuclei/muscle fiber) 
and an increase in cell size (protein/DNA ratio). This 
occurs between the ages of 4 and 13 months (110 to 360 kg) 
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in cattle (45). The increasing cellularity is a result of 
nuclei being added to a muscle fiber by mitosis of a 
partially committed myogenic cell (satellite cells). 
Satellite cells are small mononucleated cells residing 
between the plasmalemma and the basement membrane of 
muscle fibers. Satellite cells have the capability to 
synthesize DNA, divide, and synthesize the molecules 
needed for fusion into muscle fibers (44). It is 
ultimately the number of muscle fiber nuclei which 
determines the mass of skeletal muscle in a given animal 
species (46). 
The effects that many growth factors exert on 
satellite cells, are similar to their effects on embryonic 
myoblasts. While embryonic myoblasts and satellite cells 
appear functionally equivalent both in-vivo and in-vitro, 
recent evidence suggests that satellite cells are a 
distinct subclass of myogenic cells (47). This evidence 
includes morphological, growth factor responsiveness, 
expression of muscle specific proteins, and expression of 
receptors differences between the embryonic myoblasts and 
satellite cells. While considered mitotically inactive in 
mature muscle (48), recent evidence has shown that 
satellite cells can be stimulated to reenter the 
replicative phase of the cell cycle to add further to the 
myonucleii population (47). Allen and Rankin (47) 
reviewed the influence the growth factors IGF-1, FGF, and 
TGF-^, and a synthetic androgen steroid, trenbolone, have 
on growth and development of satellite cells. In primary 
cultures of rat satellite cells, FGF has been shown to 
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enhance proliferation while depressing differentiation 
(fusion). I6F-1 profoundly stimulated differentiation, 
with only a small effect on proliferation. TGP-f 
inhibited both proliferation and differentiation. The 
differentiation inhibiting effect of TGF-f could not be 
counteracted by any combination of FGF of IGF-1. However, 
the proliferation-depressing activity of TGP-f could not 
inhibit the mitogenic activity of FGF. Maximal 
stimulation of proliferation occurred in cells exposed to 
FGF and IGF-1, while maximal differentiation occurred in 
cells exposed to IGF-1. The authors described a model 
where early in satellite cell stimulation, FGF stimulates 
proliferation. At the same time, FGF and T6F-/9 inhibit 
differentiation, allowing for more proliferation. After 
the removal of these factors, IGF-1 stimulates 
differentiation and fusion of the satellite cells into the 
fibers. Female rats were injected with TBOH for two 
weeks. Muscle DNA content in muscles from TBOH treated 
rats was significantly higher than that in control rats. 
However, when the effect of TBOH was examined with 
satellite cells in culture, there was no evidence for a 
direct stimulatory effect. When cultures of satellite 
cells were prepared from control rats or TBOH treated rats 
and examined for their ability to respond to IGF-1 and 
FGF, cells from TBOH rats consistently responded with 
greater IGF-1 induced differentiation and FGF induced 
proliferation. It therefore appears that TBOH sensitized 
the satellite cells to the growth factors. 
The second phase of postnatal hypertrophy, after 13 
14 
months of age in cattle, is primarily limited to an 
increase in cell size due to increased protein deposition 
(45). IGF-1 and E6F have been shown to stimulate proteins 
synthesis and inhibit protein breakdown in primary 
multinucleated myotube cultures in vitro (49). 
It appears that IGF-1 plays an essential role in all 
stages of both prenatal and postnatal muscle growth and 
development. While it has been implicated in stimulation 
of proliferation, its major effect appears to be 
enhancement of differentiation. Therefore, any regulation 
of IGF-1 production, whether by the liver and release into 
the plasma, or directly by target tissues, would seem to 
have a major impact on skeletal muscle development. 
Gene Regulation by Steroid Hormones 
Since two of the three sections in this dissertation 
deal with steroid regulation of IGF-1 mRNA expression (for 
simplicity, the thyroid hormones and their receptors are 
considered members of the steroid "superfamily", see 
below), a brief review of gene regulation by steroid 
hormones is appropriate. The general mechanism by which 
steroid hormones react with their receptors and thereby 
regulate gene expression, as reviewed by Norman and 
Litwack (50), is as follows: A steroid hormone is carried 
through plasma bound to a binding protein. The binding 
protein protects the hormone and serves as a 
transportation mechanism. Once freed from the binding 
protein, the steroid hormone enters the cell, probably by 
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free diffusion. Inside the cell, it binds to an 
unoccupied receptor specific for that steroid to form an 
unactivated complex. The binding of the steroid hormone 
to the receptor occurs either in the nucleus or the 
cytoplasm. Following activation, the receptor/hormone 
complex translocates to the nucleus and has an increased 
affinity for DNA. Inside the nucleus, the activated 
hormone/receptor complex binds to high affinity DNA 
binding sites. These sites are located upstream from 
genes activated/regulated by the specific steroid hormone. 
Activation of a gene by a steroid hormone/receptor complex 
involves recruitment of transcription factors and RNA 
polymerase, resulting in increased transcription of mRNA 
and mediation of a specific biological response. 
All steroid hormone receptors are related in 
structure, and have been termed a "superfamily" of 
receptors (51,52). Included in this superfamily are the 
glucocorticoid, mineralcorticoid, androgen, progesterone, 
estrogen, retinoic acid, and thyroid hormone receptors. 
Based on their primary amino acid sequence, there are 
three major regions of conserved amino acids in each 
steroid hormone receptor, designated I, II, and III. 
Regions II and III are located in the C-terminal or 
hormone binding domain of the receptor. The exact 
functions of these regions are unknown, but their 
importance is suggested by their conservation. Region I 
is a highly conserved 66 amino acid sequence located 
within the interior of the receptor and contains the 
specific DNA binding domain. It is within this DNA 
16 
binding domain of the receptor that there are nine 
conserved cysteins, eight of which are thought to form two 
zinc fingers (51,52,53). The two theoretical zinc finger 
structures in the steroid hormone receptor are 21 (zfl) 
and 25 amino acid (zf2) elongated loops in the general 
shape of a finger. The base of each finger contains four 
cysteines tetrahedrically attached to one zinc molecule. 
This zinc finger region of the receptor contains the amino 
acids which serve to recognize the specific steroid 
response element (SRE) in genomic DMA adjacent to target 
genes. It has been suggested that the first finger (zfl) 
contains primary information for sequence specificity of 
binding while the second finger stabilizes binding of the 
receptor to its DNA response element (54). 
While amino acid regions II and III in the carboxy 
terminal domain of the receptor, and region I within the 
interior of the receptor are highly conserved, the N~ 
terminal region is poorly conserved in both length and 
amino acid sequence. It is this region, along with 
another located between regions I and II, that are thought 
to be responsible for the gene transcription specificity 
of each individual steroid hormone receptor complex 
(52,54). 
The SRE, or DNA region where the activated steroid 
hormone/receptor complex binds, is a short (approximately 
15 base pair) nucleotide sequence composed of two half 
sites. These half sites have a dyad axis of symmetry, or 
inverted repeat sequences of nucleotides (54). Each 
repeated sequence is thought to bind to one monomer of an 
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activated steroid hormone/receptor dimer (55). While each 
SRE is highly specific, it is interesting to note that the 
glucocorticoid and progesterone receptors bind to 
indentical SREs. Since the biological actions of these 
hormones are quite distinct, it appears that the factor 
which accounts for the specificity of action of these 
hormones is regulation of receptor expression. This has 
been demonstrated in rat hepatoma cells (56). These cells 
have a glucocorticoid receptor, but no progesterone 
receptor. Introduction of a progesterone receptor (via an 
expression vector) results in induction of glucocorticoid 
responsive genes in response to progesterone. 
It is not clear if steroid stimulation of IGF-1 mRNA 
(19,20,21) is direct, or mediated through steroid induced 
nuclear proteins. This is an exciting area of research 
and many breakthroughs are on the horizon. 
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EXPLANATION OF DISSERTATION FORMAT 
This dissertation is presented in alternate format, 
as outlined in the Iowa State Graduate College Thesis 
Manual. Use of the alternate format allows for 
preparation of independent sections that are suitable for 
submission to scientific journals. 
Three separate papers have been prepared from data 
collected from research performed to partly fulfill 
requirements for the Ph.D. degree. Each paper is complete 
in itself and has an introduction, materials and method, 
results, discussion, and citation of references. The 
closeness of the subject matter allowed a general 
discussion to be prepared. 
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ABSTRACT 
Growth hormone (GH), insulin-like growth factor-1 
(IGF-1), and thyroid hormone (T3 and T4) concentrations in 
blood plasma of 18 crossbred cattle (six bulls, six 
steers, and six heifers) were measured over an 8-h period. 
One week later at slaughter, IGF-1 production by liver 
slices and IGF-1 mRNA concentrations in skeletal muscle 
and liver were measured. Bulls had higher (P<0.05) mean 
plasma GH and GH peak amplitudes (P<0.01) than heifers and 
values for steers were intermediate between bulls and 
heifers. Baseline GH concentrations and number of GH 
peaks were not significantly different for the three 
groups. Bulls had 1.6-(P<0.01) and 3.0-(P<0.01) fold 
greater liver IGF-1 mRNA concentrations than steers or 
heifers, respectively, whereas the steers had 1.8-fold 
(P<0.05) greater IGF-1 mRNA in liver than heifers. 
Production of IGF-1 by liver slices was greater (P<0.05) 
in bulls than steers or heifers. Bulls had 1.3 fold 
greater plasma IGF-1 than steers (P<0.01), while steers 
had 1.8 fold greater plasma IGF-1 than heifers (P<0.01). 
There were no significant differences in concentrations of 
skeletal muscle IGF-1 mRNA between the three groups of 
animals. Liver IGF-1 mRNA, liver IGF-1 production, and 
plasma IGF-1 were all significantly correlated with gain 
and mean GH peak amplitude, but not with GH baseline, GH 
peak frequency, or concentrations of T3 and T4. 
Concentrations of IGF-1 mRNA in skeletal muscle were not 
correlated to gain or any parameter of the GH profile. 
Plasma concentrations of T3 were significantly (P<0.05) 
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negatively correlated to plasma GH baseline 
concentrations. Muscle I6F-1 nRNA concentration was 
negatively related to plasma T4 and T3. The results of 
this study suggest that the cascade of events starting 
with secretion of GH from the pituitary, expression of 
liver IGF-1 mRNA, and secretion of IGF-1 by the liver are 
important phenomena for growth of cattle. 
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INTRODUCTION 
Growth hormone (6H) is a determinant of serum 
concentrations of insulin-like growth factor-1 (I6F-1), a 
70-amino acid polypeptide synthesized primarily in the 
liver (1) and responsible for normal skeletal growth 
(2,3). Abundance of IGF-1 mSNA in the liver is regulated 
by GH (4-6). When high doses of GH have been administered 
to hypophysectomized rats, IGF-1 mRNA synthesis has also 
been stimulated in nonhepatic tissues (5-8). This 
observation, along with evidence showing that arterially 
infused GH has local growth-promoting properties that can 
be abolished with antiserum to IGF-1 (9) as well as the 
ability of many tissues to synthesize IGF-1 (10), suggests 
an autocrine or paracrine role of IGF-1 for control of 
growth. The importance of the contribution of hepatically 
derived circulating IGF-1 to growth, however, cannot be 
disregarded. Administration of exogenous IGF-l to 
hypophysectomized rats and Snell dwarf mice has resulted 
in stimulation of growth (3,11). 
The importance of IGF-1 synthesis in hepatic or non-
hepatic tissues of normal, intact animals in relation to 
their growth potential has not been studied. Because the 
liver is the primary source of plasma IGF-1 (1), if there 
were no differences in metabolic clearance then it seems 
that faster-growing animals would have greater IGF-1 mRNA 
concentrations as well as IGF-1 synthesis in the liver. 
However, if IGF-1 is acting primarily in an 
autocrine/paracrine fashion in response to GH, and 
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assuming gene expression is indicative of local lGF-1 
production, it seems that nonhepatic tissues of faster-
growing animals, specifically skeletal muscle, may have 
greater expression of the IGF-l gene. If IGF-l is acting 
in an autocrine/paracrine fashion in skeletal muscle, the 
importance of determinants of muscle growth other than GH, 
such as the thyroid hormones, are unknown. The purpose of 
this study was to compare IGF-l mRNA concentrations in 
liver and skeletal muscle, liver IGF-l production, and 
plasma IGF-l concentrations of cattle with different 
growth rates and relate these parameters to the nature of 
their GH secretory profiles and thyroid status. 
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HATERIALS AND METHODS 
Animals and Experimental Procedures 
Eighteen crossbred cattle, from Simmental sires and 
Angus x Charolais x Simmental and Hereford x Charolais x 
Simmental crossbred cows, were used (six as bulls, six as 
steers, and six as heifers). The cattle were born in the 
spring within a 31-day period and were maintained on 
pasture with their dams until weaning at 6.5 months of 
age. At 6 months of age, six of the males were castrated. 
At 8 months of age, all animals were adjusted to a diet 
containing on a dry basis 53.4% cracked corn, 8.0% ground 
cobs, 5.0% molasses, 30.0% dry corn gluten feed, and 1.18% 
ground limestone, 0.30% NaCl and 2.12% of a mixture to 
provide recommended concentrations of vitamin A, trace 
minerals and monensin sodium. Animals were housed in a 
common pen but individually accessed fed ad libitum by use 
of electronic gates (American Calan, Inc., Northwood, NH) 
until the end of the study (168 days). Animals were given 
fresh feed once per day, had ad libitum access to water, 
and were weighed monthly. 
At 14 months of age indwelling catheters (Tygon 
microbore tubing, 0.02mm i.d. x 0.066 mm o.d.. Fisher 
Scientific, Pittsburgh, PA) were inserted into the jugular 
vein of each animal and held in place with elastic tape. 
The catheters were maintained overnight by filling with 
sterile physiological saline containing 100 units 
heparin/ml. The next day serial blood samples were 
collected into heparin at 15-min intervals for 8 h. Blood 
samples were centrifuged and plasma was stored at -10 C 
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until assayed for 6H, IGF-1, total TA, and total T3. 
One week after blood sampling, the animals were 
killed at a commercial abattoir. Samples of blood, one 
skeletal muscle sample (Sterno-mastoid), and two samples 
of liver from the caudate lobe were obtained from each 
animal. Sections of muscle and liver weighing 
approximately 100-150 g were immediately placed in sterile 
bags, frozen in liquid nitrogen, and stored at -70 C until 
needed. Additional samples of liver weighing 10-15 g were 
placed in 250-ml Erlenmeyer flasks containing ice-cold 
sterile Hams F-12 with L-glutamine (Sigma Chemical 
Company, St. Louis, Mo); supplemented with 1% (w/v) of 
bovine serum albumin, fraction V (Boehringer Mannheim, 
Indianapolis, IN); 0.06 g/L Penicillin-6 (1662 U/mg); and 
0.10 g/L Streptomycin sulfate (750 U/mg) (this mixture 
will be referred to simply as medium). The flasks 
containing the liver samples were flushed with oxygen and 
kept in ice for approximately 1 h after which the tissue 
were sliced for incubation studies (see below). 
An estimate of muscling was calculated by measuring 
the ribeye area (cross sectional area) of the Loalssumus 
dorsi at the level of the 12th and 13th ribs. An estimate 
of subcutaneous carcass fat was obtained by measuring the 
fat thickness over the twelfth rib. 
Isolation of Nucleic Acids 
The size of IGF-1 mRNA transcripts in both the liver 
and skeletal muscle were analyzed by using Northern 
hybridizations. Quantitation of IGF-1 mRNA was achieved 
using a solution hybridization assay. For the Northern 
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analyses, total SNA was extracted from each Individual 
tissue sample by using the guanidinium isothiocyanate-
cesium chloride method (12). Briefly, 0.5 g of liver or 
1.0 g of muscle was homogenized in 8 ml of 4 M guanidinium 
isothiocyanate, layered on 4 ml of 5.7 M cesium chloride 
and ultracentrifuged at 174,000 x g for 21 h. Following 
ultracentrifugation, the RNA pellet on the bottom of the 
tube was transferred to a microfuge tube and ethanol 
precipitated. The total RNA sample was then stored at -70 
until further use. Poly A(+) RNA was isolated by using 
the oligo d(T) cellulose method (13), as modified by Lund 
et al. (14). For solution hybridizations, total nucleic 
acid (TNA) preparations from the liver samples where 
obtained by the sodium dodecyi sulfate-proteinase K 
digestion, phenol/chloroform extraction method described 
by Durnam and Palmiter (15). The amount of DNA in each 
TNA sample was determined fluorometrically by using the 
method of Labarca and Paigen (16). preparations of TNA 
from muscle were obtained by homogenizing the tissue in 
guanidinium isothiocyanate and ultracentrifugation in 
cesium chloride as already described, with the exception 
that the cesium chloride fraction was collected after 
centrifugation (17), ethanol precipitated, and DNA content 
determined as described. Muscle was done differently from 
liver because TNA from muscle prepared as described for 
liver was not satisfactory for the solution hybridization. 
Hybridization Assays 
Extracts of RNA from liver and skeletal muscle were 
analyzed by gel electrophoresis to qualitatively 
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characterize the species of IGF-1 nRNA present in bovine 
tissues. Liver poly A(+) RNA and muscle total RNA were 
separated by electrophoresis in a 1.5% agarose - 0.66 M 
formaldehyde gel (17,18) and transferred to Zeta Probe 
nylon membranes (Bio-Rad Laboratories, Richmond, CA) by 
capillary blotting procedures (19). Filters were 
prehybridized for 5 min at 65 C in 1% BSA, 1 mN EDTA, 7% 
SDS, and 0.5 M NaPO^, pH 7.2. Hybridization was performed 
in the same solution containing 1.0 x 10^ cpm/ml of human 
IGF-1 cDNA (20) labeled with random priming. A gel-
purified Pst I insert of plasmid containing the 664 bp 
hIGF-1 (coding for 14 residues of the pre-pro- protein, B, 
C, D, and E peptides, and 284 3' UTR nucleotides) was 
labeled to a specific activity of approximately 1 x 10^ 
cpm//ig by using (^^P)dCTP and random prime reagents 
obtained from Amersham (Arlington Heights, IL). Labeled 
probe was separated from unincorporated nucleotides by 
using a Sephadex 6-50 (Pharmacia, Piscataway, NJ) column 
(0.7 X 30 cm). After an overnight hybridization, filters 
were washed twice at room temperature for 30 min each in 
2X SSC, 0.1% SDS; twice at 65 C for 45 min each in 2X SSC, 
0.1% SDS; and finally twice at 42 C for 30 min each in 
O.IX SSC, 0.1% SDS. Autoradiography was performed by 
exposing Kodak X-Omat AR film (Eastman Kodak, Rochester, 
NY) to the membranes at -70 C in the presence of two 
intensifying screens (Du Pont Cronex*Lightning Plus, Du 
Pont Company, Wilmington, DE) for up to 2 days. 
Transcript size was determined by comparison with RNA size 
standards (Bethesda Research Laboratories, Gaithersburg, 
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MD) . 
Quantitation of IQF-1 nRNA was done by solution 
hybridization as described by Durnam and Palmiter (15) and 
modified by Mathews et al. (6). The 664 bp human IGF-1 
cDNA probe (20) was subcloned into the pGEM 3Z(+) plasmid 
(Promega Biotech, Madison, WI) (21) in both orientations 
and sequenced by the Sanger dideoxy method (22). An 
antisense cRNA probe was synthesized according to the 
protocol of Melton et al. (23) by using (^^S)UTP. The 
labeled hIGF-1 cRNA probe was hybridized to triplicated 
TNA or RNA samples from each individual animal in 40 pi 
incubation buffer containing 0.6 M NaCl, 20 mM Tris'HCl 
(pH 7.5), 4 mM EDTA, 0.1% SDS, 10 mM dithiothreitol, 25% 
formamide, and approximately,1.8 x 10^ cpm labeled cRNA 
probe. After an overnight incubation at 72 C, samples 
were treated with 40 pg of ribonuclease A (Sigma 
Chemicals, St. Louis, MO) and 250 units of ribonuclease T^ 
(Boehringer Mannheim, Indianapolis, IN) in the presence of 
100 nq of herring sperm DNA in a total volume of 1 ml at 
37 C for 45 min. Protected probe was precipitated by 
using 100 pi of 6 M TCA, collected on #34 glass-fiber 
filters (Schleicher and Schuell, Keene, NH) and counted in 
a scintillation counter. The hybridization signal was 
compared with that of a standard curve of known amounts of 
a synthetic single stranded 664 bp hIGF-1 DNA, which was 
synthesized from the pGEM 3Z(+) plasmid (24). 
Liver Incubation 
Liver samples were removed from the flasks, blotted 
dry, and sliced by using a Stadie-Riggs Microtome (Thomas 
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Scientific, Swedesboro, NJ). Slices, 0.5-mm thick, from 
each animal were weighed, rinsed in medium (composition 
given above), and placed into four 25-ml Erlenmeyer flasks 
containing 3 ml of fresh medium (40-120 mg liver/flask). 
Immediately after addition of the liver slices, the flasks 
were flushed for 15 sec with oxygen, capped, and placed in 
a water bath maintained at 37 C. The liver slices were 
incubated for 18 h and the atmosphere above the medium was 
gassed with oxygen every 2-4 h. In preliminary 
experiments, bovine liver slices, treated in this manner 
continued to consume oxygen, decreasing to 20% of initial 
rates at 24 h. Accumulation of IGF-l in the medium 
increased with time and was increased 25 to 40% by the 
addition of bovine 6H. At t^e conclusion of the 18 h-
incubation, the medium was removed, frozen, and stored 
at -10 C until assayed for IGF-l. 
IGF-l Extraction 
Samples of liver were cut from frozen tissue and 
pulverized in liquid nitrogen. The pulverized tissue was 
homogenized in 1 M acetic acid as described by O'Ercole et 
al. (10). Plasma and samples of incubation medium were 
acidified with addition of 1 ml of 0.5 M HCl to 250 nl of 
sample. IGF-l was extracted from all acidified samples by 
using a modified method of Goddard et al. (25). Sep-pak 
columns (Waters Associates, Milford, MA) were 
prewashed in order with 5 ml isopropanol, 5 ml HPLC grade 
methanol, and 5 ml of 4% acetic acid. After application 
of the acidified sample, the column was washed with 20 ml 
of 4% acetic acid. Samples were eluted with 4 ml of 
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methanol. Methanol was evaporated to dryness with a 
stream of air at 37 C, and the samples were reconstituted 
with assay buffer. 
Radioimmunoassays 
Plasma GH and I6F-1 concentrations were determined by 
using double-antibody radioimmunoassay techniques. Ovine 
GH, purified from ovine pituitary glands (26) and human 
IGF-1 (recombinantly derived, IMCERA Bioproducts, Inc., 
Terre Haute, IN ) were iodinated by the chloramine-T 
method of Greenwood et al. (27). The labeled hormones 
were purified again immediately before use by exclusion 
chromatography using Sephadex 6-150 and the buffer for 
each respective assay. 
The GH RIA components w#re: iodinated ovine GH, 
reference bovine GH (28), rabbit antibovine GH (raised 
against bovine GH), normal rabbit serum, and goat-
ant irabbit IgG (Vanguard Scientific, St. Louis, MO). The 
reagents were diluted in pH 7.6 phosphate-buffered saline 
(0.28 M phosphate, 0.15 M NaCl, and 0.025 M disodium 
EDTA). Samples and reference GH were incubated with 
antibovine GH for 2 days at 4 C before addition of labeled 
GH. The tubes were incubated at 4 C for an additional 2 
days before separation of the labeled GH bound to antibody 
with antirabbit IgG. Bovine thyroid stimulating hormone, 
interstitial cell-stimulating hormone, prolactin and 
plasma from hypophysectomized cattle were not active in 
this assay. Sequential dilutions of bovine plasma and 
extracts of bovine anterior pituitary gland paralleled the 
standard curve obtained with the bovine GH standard. The 
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GH RIA had intra- and inter-assay coefficients of 
variation of 2.4 and 4.6%, respectively. 
At the time of GH assay, plasma samples from times 0-
75, 90-165, 180-255, 270-345, and 360-480 (min) were 
pooled for analysis of IGF-1. The IGF-1 RIA components 
were: iodinated human IGF-1, reference human IGF-1 (IMCERA 
Bioproducts Inc.), rabbit-antihuman IGF-1 (Somato C22V01, 
raised against human IGF-1 isolated from plasma and 
obtained from National Hormone and Pituitary Program, 
Baltimore, MD), normal rabbit serum, and goat antirabbit 
IgG (Vanguard Scientific). The reagents were diluted in 
pH 7.5 phosphate buffer (0.03 M phosphate, 0.01 M disodium 
EDTA and containing 200 mg protamine sulfate and 200 mg 
sodium azide/L). Samples an^ reference IGF-1 were 
incubated with antihuman IGF-1 for 2 days at 4 C before 
addition of labeled IGF-1. The tubes were incubated at 4 
C for an additional 2 days before separation of the 
labeled IGF-1 bound to antibody with antirabbit IgG. This 
antiserum had 0.5% cross reaction with IGF-2 and less than 
0.1% with insulin. Extracted bovine plasma and human 
IGF-1 standard curves demonstrated parallelism. The IGF-I 
RIA had intra- and inter-assay coefficients of variation 
of 2.8 and 9.4%, respectively. 
Concentrations of plasma T4 and T3 were measured 
using commercial radioimmunoassay kits (Diagnostic 
Products Corporation, Los Angeles, CA 90045). The ranges 
of concentrations of standards were 10 to 240 ng/ml for T4 
and .2 to 6 ng/ml for T3. Serial dilutions of bovine 
plasma were assayed with both the T4 and T3 assays and 
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found to parallel the standard curves. Validation of the 
assays were also done by adding a fixed aliquot of bovine 
plasma to each of the standards, the results of which also 
paralleled the standard curve. The plasma samples were 
assayed at 25 and 100 ul for the T4 and T3 assays, 
respectively. 
Statistical Analysis 
Growth hormone secretory peaks were determined by a 
mathematical model similar to that used by Riley et al. 
(29). The mean of all values falling below the overall GH 
mean for the 8-h period was calculated for each animal and 
was termed the inlying mean. A GH peak was at least 50% 
higher than the inlying mean and contained at least two 
points elevated above the inlying mean. The mean 
amplitude of the GH peaks was defined as the average of 
the maximum values of each of the GH secretory peaks. 
After identification of the peaks, all peaks and adjacent 
points above the inlying mean were removed from the GH 
profile, and the average of the remaining points was 
termed mean baseline GH. 
Overall effects of sex and castration were analyzed 
as a completely random design by using analysis of 
variance followed by F and least significant difference 
tests (30). Correlations were calculated by using linear 
regression, and significance of correlation coefficients 
was determined by using the Fisher null hypothesis (30). 
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RESULTS 
Growth rates over the 168-day period and carcass 
measurements are reported in Table 1. Bulls were shown to 
have the greatest daily gain and the most efficient use of 
feed. There were no significant differences found in 
daily feed intake among the three groups. Carcass weight 
and ribeye area were greater (P<0.05) and backfat was 
significantly less in bulls compared with heifers. A 
summary of the 6H profiles, IGF-1 parameters, and thyroid 
hormone concentrations are given in Table 2. Plasma GH 
profiles were asynchronous for all animals and showed 
considerable variation between animals within each group. 
The mean GH concentrations w^re 2.3 times higher (P<0.05) 
in bulls than in heifers. Baseline GH concentrations were 
not different among the three groups of animals. The 
number of secretory peaks was variable among individuals, 
and there were no significant differences. GH profiles of 
heifers tended to have a few small GH peaks, with a mean 
magnitude of 1.8 ng/ml. Steers and bulls exhibited nearly 
twice the number of peaks as seen in heifers as well as 
significantly greater (P<0.01) amplitudes of GH peaks. 
Mean amplitude of GH peaks in bulls was 1.7 times greater 
(P<0.01) than in steers. 
41 
Table 1. Growth and carcass characteristics of bulls, 
steers, and heifers (n « 6 of each) 
Parameter Bulls Steers Heifers SEM* 
Birth wt., kg 40.0 43.0 41.9 2.5 
Weaning wt., kg 254.9b 245.1b 218.7® 11.4 
Feedlot phase 
Daily gain, kg 1.64b l.45bc 1.26® 0.13 
Feed/Gain, kg/kg 6.20b 6.57b® 7.44® 0.44 
Carcass characteristics 
Carcass wt., kg 359.6^ 328.7b® 304.1® 17.6 
Loin eye area. b 
square cm 95.7° 84.3® 83.6® 5.8 
Backfat, cm 
JQ CO 0
 1.27® 1.25® 0.2 
^Standard error of nean". 
^°Heans within a row without a common superscript 
differ (P<0.05). 
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Table 2. Comparison of plasma GH profiles and I6F-1 
parameters between bulls, steers, and heifers 
Parameter Bulls Steers Heifers SEM* 
Mean plasma GH 
concentration, v> ho o 
ng/ml 3.7® 2.9®° 1.6° 0.9 
Mean GH Baseline, 
ng/ml 1.7 1.6 1.4 0.4 
Mean GH peak 
number 4.0 4.5 2.3 1.1 
Mean GH peak amplitude,*. _ ^ 
ng/ml 10.1® 5.8° 1.8* 2.7 
Liver IGF-1 mRNA abundance, _ ^ 
amol/ug DNA 3.29° 2.02° 1.11° 0.29 
Liver IGF-1 production,w _ _ 
ng/g 54.6® 34.7° 30.5° 10.4 
Mean plasma IGF-1 
concentration, h o h 
ng/ml 428® 327° 186* 66 
Muscle IGF-1 mRNA 
abundance, 
amol/ug DNA 0.089 0.059 0.071 0.010 
Total T4, ng/ml 74.1® 89.7^ 85.1®^ 4.6 
Total T3, ng/ml 2.1 2.5 2.2 0.58 
^Standard error of mean. 
^°'^Means within a row without a common superscript 
differ (P<0.05). 
®^Means within a row without a common superscript 
differ (P<0.07). 
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Examples of Northern analysis of liver and muscle 
IGF-1 mRNAs from two animals are shown in Figures l and 2 ,  
respectively. The major IGF-1 transcripts in liver were 
approximately 8.0, 5.6, and 2.0 Kb. A 0.8 Kb species was 
present in very low relative abundance. Similar IGF-1 
transcripts were observed in skeletal muscle, except that 
2.0- and 0.8-Kb species seemed to be present in much lower 
relative abundance. Each of the four transcripts were 
present in the liver and skeletal mRNA of each animal. 
Serial dilutions of a TNA sample from liver or RNA 
from muscle resulted in a curve paralleling that of the 
single-stranded hIGF-1 DNA used as standard in each 
solution hybridization assay^ The labeled antisense IGF-1 
cRNA did not hybridize to serial dilutions of yeast RNA (0 
to 100 ug). A 35g-iabeled sense IGF-1 cRNA did not 
hybridize to serial dilutions of liver or muscle RNA. 
Results of the solution hybridization assays are shown in 
Table 2. Bulls had 1.6- (P<0.01) and 3.0- (P<0.01) fold 
greater liver IGF-1 mRNA than either steers or heifers, 
respectively. Steers had 1.8-fold greater concentration 
of IGF-1 mRNA in liver than did heifers (P<0.05). Similar 
relative differences among the three groups of animals 
were obtained when using liver RNA slot blots hybridized 
to a labeled phIGF-1 cDNA (data not shown). 
Production of IGF-1 by liver slices was significantly 
greater (P<0.05) for bulls than for steers or heifers. 
Liver content of IGF-1 seemed to be greater for bulls than 
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Figure 1. Samples of hybridizations of human IGF cDNA to 
bovine liver RNA. Approximately twenty 
represents the mRNÂ Erom one Lvidual animal 
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8.6-
5.3-
Figure 2. Samples of hybridizations of human IGF cDNA to 
bovine skeletal muscle RNA. Approximately 
twenty micrograms of total RNA from skeletal 
muscle of bull (B), steer (S), or heifer (H) 
were resolved on a denaturing 
agarose/formaldehyde gel. transferred to a 
nylon membrane, and hybridized to a 32P labeled 
human IGF-1 cDMA as described in Materials and 
Each lane represents the 
ual animal 
rom one 
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steers or heifers, but the IGF-1 in the liver seemed to be 
due to the concentration of hormone in residual blood in 
the tissue. After correction for residual plasma by 
reacting hemoglobin with benzidine (31), liver content of 
IGF-1 was not significantly different from zero (P>0.05) 
for all three groups (data not shown). Liver slices were 
washed in medium before incubation to remove residual 
blood plasma, so it is unlikely that the production data 
represent leaching of IGF-1 present in tissue at the time 
of sampling. 
Concentrations of plasma IGF-1 in bulls were 1.3 
times (P<0.01) that of steers and 2.3 times (P<0.01) that 
of heifers (Table 2). Plasmp concentrations of IGF-1 
varied little over the 8-hour period. 
Although bulls had 52% greater IGF-1 mRNA in muscle 
than steers, there was not a statistically significant 
difference in IGF-1 mRNA abundance in muscle among the 
three groups of animals due to variation of muscle IGF-1 
mRNA in bulls. Bulls had the highest concentration of 
IGF-1 mRNA in muscle, whereas the heifers had the next 
greatest and the steers the least concentration. Similar 
relative differences were obtained when using muscle RNA 
slot blots hybridized to a labeled phIGF-1 cDNA (data 
not shown). Bulls and steers had approximately 35-fold 
greater IGF-1 mRNA abundance in the liver than in the 
muscle, whereas heifers had only 15-fold higher 
concentrations of IGF-1 mRNA in the liver compared with 
muscle. The steers had 20 (P<.07) and 19% greater plasma 
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T4 and T3, respectively, than the bulls, while the heifers 
were intermediate between the steers and bulls. 
Correlation coefficients for the relationship of 
liver IGF-1 mRNA, liver IGF-1 production, plasma IGF-1, 
and skeletal muscle IGF-1 mRNA with certain growth and 
plasma GH profile parameters are given in Table 3. 
Average daily gain was significantly correlated to liver 
IGF-1 mRNA abundance, liver IGF-1 production, and plasma 
IGF-1 (P<0.01), but not correlated to skeletal muscle IGF-
1 mRNA abundance. Liver IGF-1 mRNA abundance, liver IGF-1 
production, and plasma IGF-1 were significantly correlated 
to mean GH peak amplitude, but not to GH peak frequency or 
mean GH baseline. Skeletal muscle IGF-1 mRNA abundance 
was not correlated to any of, the parameters of the GH 
profile. Liver IGF-1 mRNA abundance was significantly 
correlated to liver IGF-1 production (P<0.05) as well as 
plasma IGF-1 (P<0.01). Although liver IGF-1 production in 
vitro was not significantly correlated to IGF-1 
concentrations in plasma taken 7 days before the liver 
samples, a significant correlation was found between liver 
production of IGF-1 and IGF-1 concentrations in plasma 
obtained from the animals at the time of death (P<0.01) 
(data not shown). The mean concentrations of IGF-1 in 
these plasma samples and the differences among the three 
groups of animals were similar to data obtained from the 
blood samples taken during the longer sampling period the 
previous week. 
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Table 3. Correlation of liver IGF-1 mRNA, liver IGF-1 
?reduction, plasma IGF-1, and skeletal muscle GF-1 mRNA with certain growth and plasma GH 
profile parameters (data pooled from all 18 
animals) 
Item Liver IGF-1 Liver IGF-1 Plasma Muscle IGF-1 
mRNA Production IGF-1 mRNA 
(amol/ug DNA) (ng/g) (ng/ml) (amol/ug DNA) 
Average daily 
gain, kg .77 _ .59 .67 .05 
(<0.01)® (<0.01) (<0.01) 
Mean plasma 
GH, ng/ml .64 .21 .61 -.06 
(CO.01) (<0.01) 
Mean GH 
baseline, 
ng/ml .04 .20 .30 -.26 
Number of GH 
peaks .40 .13 .45 .00 
Mean GH peak 
amplitude, 
ng/ml .73 .47 .67 .19 
(<0.01) (CO.05) (CO.01) 
Liver IGF-1 
mRNA, 
amole/ug DNA .. .55 .85 .13 
(CO.05) (CO.01) 
Liver IGF-1 
production, 
ng/g .55 ... .42 -.02 
(CO.05) 
^Probability that correlation coefficient could not 
be arrived at with a pair of random, unrelated variables. 
No P-value under a correlation coefficient indicates not 
significant, null hypothesis cannot be rejected. 
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Table 4. Correlation of total plasma T4 and T3 with liver 
I6F-1 nRNA, liver IGF-i production, plasma IGF-1, 
skeletal muscle IGF-1 mRNA, plasma GH profile 
parameters, and growth (data pooled from all 18 
animals) 
Item Plasma T4 Plasma T3 
(ng/ml) (ng/ml) 
Average daily 
gain, kg -.37 -.04 
Mean plasma 
GH, ng/ml 
Mean GH 
baseline, ng/ml 
-.20 
-.14 1
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•
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O
U
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Number of GH 
peaks -.04 
(<0.05) 
-.35 
Mean GH peak 
amplitude, ng/ml -.29 ' 1 w 
Liver IGF-1 
mRNA, amol/ug DNA —. 30 0
0 rH 1 
Liver IGF-1 
production, ng/g -.10 .24 
Plasma IGF-1, ng/ml -.37 -. 20 
Skeletal muscle IGF-1 
mRNA, amol/ug DNA — .44 
(<0.07) 
-.43 
(<0.07) 
Probability that correlation coefficient could not 
be arrived at with a pair of random, unrelated variables. 
No P-value under a correlation coefficient indicates not 
significant, null hypothesis cannot be rejected. 
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The correlation coefficients for the relationship of 
plasma T4 and T3 with liver IGF-1 mRNA, liver IGF-1 
production, plasma IGF-1, skeletal muscle IGF-1 mRNA, 
plasma GH profile parameters, and growth are shown In 
Table 4. Most of the relationships between these 
parameters and thyroid status were negative. Plasma T3 
was negatively related to mean plasma GH, and the primary 
component of the GH profile it was negatively correlated 
to was mean GH baseline concentrations. While liver IGF-1 
mRNA was not correlated to plasma T4 an T3, skeletal 
muscle IGF-1 mRNA was negatively related to plasma T4 and 
T3 concentrations (P<0.07). 
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DISCUSSION 
The males used In our study grew faster than the 
females before as well as after weaning. Castration of 
the males resulted in growth intermediate between bulls 
and heifers. Thickness of subcutaneous fat, cross-
sectional area of longissimus dorsi muscle, and body 
weight gain per unit of feed indicated that bulls had more 
muscle and less fat than heifers. These differences are 
in agreement with previous comparisons of the growth of 
bulls, steers, and heifers, which indicated that bulls 
were superior to steers and heifers in rate of gain, feed 
utilization, and yield of lean meat (32). 
GH profiles of bulls and steers were characterized as 
having similar baseline and frequency of periods of 
secretion but greater amplitude of GH peaks as compared 
with heifers. Female cattle did not have higher baseline 
concentrations of GH than males as reported for rats (33). 
The male pattern of GH secretion observed in bulls seemed 
to be partly retained in steers that had not been exposed 
to testicular secretions for 8 months. These animals were 
castrated at 6 months of age, which is prepubertal in 
cattle. Neonatal imprinting, by testosterone, of 
hypothalamic regulation of GH secretion has been suggested 
(34) as the reason for retention of some of the male GH 
characteristics after castration of rats. 
The negative correlation between plasma T3 
concentrations and mean plasma GH or GH baseline 
concentrations was not expected. Secretion of GH has been 
shown to be impaired during hypothyroidism in rats (35), 
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and In vitro, thyroid hormones have been shown to 
stimulate GH gene transcription as well as GH synthesis 
and secretion (36,37). 
The size and number of IGF-1 mRNA transcripts found 
in liver of cattle were similar to those reported for rat 
(4,5) and human (38) liver. The primary sequence of 
bovine IGF-1 is identical to human IGF-1 (39) and 96% 
homologous to rat IGF-1 (5). 
There was a significant correlation between plasma GH 
and abundance of hepatic IGF-1 mRNA in these animals. The 
stimulatory effect of exogenous GH on liver IGF-1 mRNA has 
been well documented in GH-deficient rats (4,5,6). We 
have now shown in this study that the range in variation 
of endogenous plasma GH typically found in cattle of 
different sexes is related to concentration of IGF-1 mRNA 
in liver. 
The greater concentration of IGF-1 in plasma of bulls 
could be from several tissues or the result of decreased 
metabolic clearance. The correlation of liver IGF-1 mRNA 
concentrations with IGF-1 production and plasma 
concentrations of IGF-1 suggest that a significant portion 
of the increased plasma IGF-1 concentrations observed in 
bulls resulted from increased synthesis and secretion of 
IGF-1 from the liver. Although they were not significant, 
correlations between plasma thyroid hormone concentrations 
and liver IGF-1 status tended to be negative and similar 
to the relationship between plasma thyroid hormones and 
plasma GH measurements. 
Though overall mean GH concentration was correlated 
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with abundance of liver IGF-1 mRNA and plasma iGF-1 
concentration, all measurements of hepatic IGF-I status of 
these animals were significantly related to amplitude of 
GH peaks rather than to baseline concentrations or number 
of GH peaks. The GH secretory pattern of male rats 
characterized as having higher amplitude than female rats 
is associated with faster growth (33,34). In 
hypophysectomized rats, administration of GH in a pattern 
mimicking endogenous secretion was more effective than 
continuous infusion for increasing growth (40) or 
increasing IGF-1 mRNA concentration in skeletal muscle and 
rib growth plates (8). In a study with steers, augmenting 
endogenous secretion with exogenous GH increased nitrogen 
retention, but the response was not influenced by pattern 
of administration (41). 
In contrast to liver, concentration of IGF-1 mRNA in 
skeletal muscle was not correlated with any parameter of 
the plasma GH profile. Reports of the effects of GH on 
expression of the IGF-1 gene in muscle are conflicting. 
While Tollefsen et al. (42) reported GH had no effect on 
IGF-1 mRNA in differentiating mouse myoblast C2 cells, 
abundance of IGF-1 mRNA in skeletal muscle has been shown 
to be stimulated by high doses of GH in rats (5,43). It 
may be that expression of IGF-1 mRNA in skeletal muscle of 
the cattle in this study was less sensitive to the 
narrower range of plasma GH concentrations as compared 
with muscle of rats exposed to high levels of GH. To our 
knowledge, the negative relationship between muscle IGF-1 
mRNA and plasma T4 and T3 has not been previously 
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observed. Because physiological concentrations of thyroid 
hormones stimulate skeletal muscle proteolysis through 
regulation of various lysosomal enzymes including RNAse 
(44), it is possible there is less I6F-1 mRNA 
degradation/turnover in the muscle of cattle with lower 
plasma T3 and T4 concentrations. 
Studies in cattle have shown that growth of skeletal 
muscle is a combination of increasing cellularity (number 
of nuclei/muscle fiber) and an increase in cell size 
(protein/DNA ratio) between the ages of 4 and 13 months 
(110 to 360 kg). Skeletal muscle growth after 13 months 
is limited to an increase in cell size (45). The results 
of this study suggest that differences in skeletal muscle 
growth among the animals used, which at this stage of 
their maturity would be primarily hypertrophy in nature, 
could not be attributed to solely an autocrine/paracrine 
property of IGF-1. Studies showing that the expression of 
rat skeletal muscle IGF-1 mRNA declines during postnatal 
development (46), circulating plasma IGF-1 is correlated 
to growth rates of mini poodles (47) and exogenous IGF-1 
stimulates growth of hypophysectomized rats and dwarf mice 
(3,11), along with our observations suggest that the role 
of IGF-1 as an endocrine modulator of growth is important. 
The autocrine or paracrine effects that IGF-1 might exert 
on increasing cellularity or cell size in the muscle of 
younger cattle has not been studied. 
The data from our study suggest that the episodic 
nature of endogenous GH secretion, especially the 
amplitude of the GH peaks, is important for growth. The 
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differences in plasma IGF-1 between the three groups of 
animals in this study seemed to be due to liver synthesis 
and secretion. While the IGF-1 status of the liver was 
related to growth, skeletal muscle IGF-1 mRNA 
concentrations were not related to growth or to any 
parameter of the GH profile. 
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SECTION II. 
THE EFFECTS OF GH AND/OR ESTROGEN ON GH 
AND IGF-1 IN PLASMA AND IGF-1 mRNA IN LIVER 
AND SKELETAL MUSCLE OF CATTLE 
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ABSTRACT 
The acute and chronic effects that growth hormone 
(GH), estrogen (Eg), or combinations of the two exert on 
plasma GH profiles, liver and skeletal muscle IGF-1 mRNA 
concentrations, and plasma IGF-1 concentrations in 
castrated male cattle were evaluated. Cattle given GH 
were injected so daily with 150 ug/kg BW recombinant bGH, 
and those given Eg received a single sc silicon rubber 
implant containing oestradiol 17-f (approximate release 
60ug/day). The acute response to GH and/or Eg was 
determined by sampling blood for a 6h period starting 1.5 
and 40.5 h, after initiation of GH and Eg treatment, 
respectively. Samples of liver and skeletal muscle 
(semimembranosus) were obtained by biopsy 9 and 48 h after 
initiation of GH and Eg, respectively. Steers given GH or 
GH+Eg had 6.0 (P<0.05) and 6.6 (P<0.05) fold greater liver 
IGF-1 mRNA concentrations than control steers, and 3.4 
(P<0.05) and 3.7 (P<0.05) fold greater liver IGF-1 mRNA 
concentrations than steers given Eg. Steers given Eg had 
1.8 fold (P<0.05) greater liver IGF-1 mRNA concentrations 
than control steers. Steers given Eg, GH, and GH+Eg had 
approximately 1.4 fold greater (P<0.05) plasma IGF-1 
concentrations than control steers. There was no 
significant acute effect of GH or Eg on skeletal muscle 
mRNA concentrations. The chronic response to these same 
treatments was determined by sampling blood for a 8h 
period starting 16 h after the 14th daily GH injection, 
and 15 d after implanting Eg and sampling liver and 
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skeletal muscle immediately after the blood samples. 
Steers receiving Eg implants had approximately 80% greater 
(P<0.05) mean plasma GH and 2 fold greater GH peak 
concentrations (P<0.05) than control steers. Animals 
receiving GH had approximately 1.6 fold greater (P<0.05) 
concentrations of liver IGF-1 mRNA than animals receiving 
either GH+Eg or Eg, which had approximately 1.6 fold 
greater (P<0.05) concentrations of liver IGF-1 mRNA than 
control steers. Eg significantly reduced the IGF-l mRNA 
response to GH in the liver. Steers given GH and GH+Eg 
had greater (P<0.05) plasma IGF-1 concentrations than 
either control or Eg steers. Steers receiving GH+Eg had 
greater (P<0.05) concentrations of skeletal muscle IGF-1 
mRNA than either GH or control steers. Steers receiving 
Eg had higher (P<0.05) concentrations of IGF-1 mRNA in 
skeletal muscle than controls. There was a significant 
correlation of liver IGF-1 mRNA with plasma IGF-1 
concentrations, mean plasma GH and amplitude of GH peaks 
in control steers and those given GH. These relationships 
were absent in steers implanted with Eg. The correlation 
between plasma IGF-1 concentration and muscle IGF-1 mRNA 
concentration was significant in the steers implanted Eg, 
but not in GH and C steers. The results of this study 
suggest Eg and GH are anabolic in cattle through 
independent, although interactive pathways, and both 
endocrine and autocrine/paracrine actions of IGF-1 may 
contribute to growth of cattle. 
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INTRODUCTION 
Estrogens (Eg) are anabolic In cattle, Increasing 
muscle and bone tissue deposition (1). Because exogenous 
Eg Increase concentrations of plasma growth hormone (GH) 
(2), and many of their anabolic effects are similar to 
those of exogenous GH, it was proposed that the mode of 
action of exogenous Eg on growth of cattle was mediated 
through stimulation of the pituitary GH/hepatic IGF-1 axis 
(1). Recent evidence has shown that growth of cattle was 
stimulated similarly by exogenous GH and Eg, even though 
plasma IGF-1 concentrations were significantly higher in 
GH treated animals (3). The*combination of GH and Eg 
stimulated growth beyond that observed with either GH or 
Eg alone, with no further increase in plasma GH or IGF-1. 
These observations raise questions about the theory that 
exogenous Eg acts soley through stimulation of the 
pituitary. Because IGF-1 can be produced locally and act 
in an autocrine/paracrine manner to stimulate growth in 
target tissues in response to Eg (4,5,6), the possibility 
exists that the effect of exogenous Eg on growth of cattle 
could be mediated through production of IGF-1 in skeletal 
and muscle tissues. Therefore the objectives of this 
study were to determine what effects exogenous GH, Eg or 
GH+Eg have on the pituitary GH/hepatic IGF-1 axis, as well 
as on skeletal muscle in growing steers, by measuring 
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their effects on plasma 6H profiles, concentration of IGF-
1 mSNA in liver and skeletal muscle, and plasma I6F-1 
concentration. 
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MATERIALS AND METHODS 
Animals 
Twenty-four crossbred castrated male cattle (steers, 
castrated at 5 months) approximately 12 months of age and 
weighing between 380 and 450 kg were randomly allotted to 
four treatment groups, control, GH, Eg, and GH+Eg. The 
animals were housed in an outdoor pen with access to open 
shelter and were fed as a group ad libitum twice daily a 
diet containing 79% cracked corn, 12% ground cobs, 4% 
molasses, and 5% supplement. 
Hormone Treatment 
Estradiol 17-/9 in a silicon rubber implant 
(Compudose; Lilly Research Laboratories, Greenfield, IN; 
approximate release 60ug/day) was placed sc on the back of 
the ear on day -2. Recombinant bovine GH (Lilly Research 
Laboratories, Greenfield, IN) suspended in .025 M NaHPOg, 
.025 M NagPOg, .154 M NaCl buffer, pH 9.3, was given as sc 
injections of 150 ug/kg body weight starting on day 0 and 
continued until day 13. Animals not receiving GH were 
given daily sc injections of buffer used to dilute the GH. 
Blood Sampling 
The acute and chronic effects of the exogenous 
hormones were studied by taking samples of blood, liver 
and skeletal muscle on days 0 and 13, respectively. On 
the day prior to being bled, indwelling catheters (Tygon 
microbore tubing, 0.02 mm i.d. x 0.066 mm d.d., Fisher 
Scientific, Pittsburgh, PA) were inserted into the jugular 
vein and held in place with elastic tape. The catheters 
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were kept patent overnight by filling with sterile 
physiological saline containing 100 u heparin/ml. The 
following day the animals were housed in an enclosed 
shelter and loosely restrained by haltering in individual 
stalls. For the acute phase of the study, animals 
received a sc injection of either GH or buffer at hour 0. 
Serial blood samples were collected into 25 ul of sterile 
saline containing 5000 u heparin/ml at 15 minute intervals 
for a six hour period, starting at hour 1.5. At hour 9 a 
sample of liver and skeletal muscle (semimembranosus) were 
obtained by biopsy. For the chronic phase of the study, 
serial blood samples were collected as before for an eight 
hour period starting at h 16 (hour 0 was the 14th sc 
injection of GH on day 13). Biopsy of the liver and 
skeletal muscle biopsy were obtained following the last 
blood sample. Blood samples were immediately centrifuged 
and plasma was stored at -20 C until analysis for GH, IGF-
1, total T4, and total T3. 
Biopsies 
Liver and muscle biopsies were obtained from each 
animal as follows. The samples were taken from conscious 
animals restrained in a squeeze chute. Small areas 
between the eleventh and twelfth ribs and the area over 
the semimembranosus muscle were shaved, disinfected with 
Pharmadine (Sherwood Pharmaceuticals Company, Mahwah, NJ), 
and wiped clean with gauze soaked in 0.8% (v/v distilled 
water) Zephiran Chloride (17% alkylbenzyldimethylammonium 
chlorides; Winthorp Laboratories, New York, NY). 
Xylocaine (2% Lidocaine Hydrochloride; Astra 
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Pharmaceutical Products, Westborough, MA) was used as 
local anesthetic. For the liver biopsies, 6 ml was given 
into the skin and intercoastal muscle. For the muscle 
biopsies, 15 ml was given, 10 ml of which was given 
subcutaneously, and the remaining 5 ml was given 3 to 4 
inches deep in the semimembranosus muscle. Five minutes 
later, an incision approximately 1.3 cm in length was made 
between the eleventh and twelfth ribs. The cannula (0.8 
id X 31 cm) and trocar machined to fit inside the cannula 
were modified from the description by Hughes (7) and made 
at the Iowa State University Engineering Research 
Institute Machine Shop. The trocar and cannula, was 
disinfected by storing in 0.8% Zephiran Chloride, were 
inserted through the incision. The liver was located 
using the trocar as a probe and a biopsy obtained by 
turning the cannula into the liver with even pressure. 
After removal, the liver sample was placed in a sterile 
bag, immediately frozen on dry ice, and stored at - 70 
until further use. After 5 minutes, a 5 cm incision was 
made to expose the semimembranosus. A stainless steel 
cannula (1.0 id x 11 cm), sharpened at one end, 
disinfected by storing in 0.8% Zephiran Chloride. After 
turning the cannula into the muscle, a vacuum was applied 
with a hypodermic syringe and the cannula inclined from 
90° to 45° with inward pressure. This sheared the muscle 
plug. The muscle biopsy was removed, placed in a sterile 
bag, immediately frozen on dry ice, and stored at - 70 C 
until further use. The incisions were cleaned with 
sterile gauze and closed with disposable skin staples (3M 
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Medical Division, St. Paul, MN). The areas were covered 
with Furacin (0.2% Furacin; Norden Laboratories, Lincoln, 
NE) and the animals given an intramuscular injection of 
Combiotic (penicillin and dihydrostreptonycin, Pfizer, 
Inc. NY). 
Radioimmunoassay 
Plasma 6H and I6F-1 concentrations were determined 
using double-antibody radioimmunoassay (RIA) techniques as 
described (8). Concentrations of plasma thyroxine (T4) 
and triiodothyronine (T3) were measured using commercial 
radioimmunoassay kits (Diagnostic Products Corporation, 
Los Angeles, CA 90045) described previously (8). 
Nucleic Acid Isolation 
Nucleic acids were isolated from muscle and liver as 
described previously (8). Briefly, total RNA was isolated 
by using guanidium isocythiocyanate-cesium cloride (9), 
while total nucleic acid (TNA) preparations from the liver 
samples were obtained by the sodium dodecyl sulfate-
proteinase K digestion, phenol/chloroform extraction 
method described by Durnam and Palmiter (10). The 
concentrations of TNA and RNA were determined 
spectrophotometrically by measuring the O.D. at 260. The 
integrity and concentration of RNA was established using 
agarose gel electrophoresis. The amount of DNA in each 
TNA sample was determined by digesting an aliquot of TNA 
with ribonuclease A, extracting with phenol/chloroform and 
chloroform, and precipitating the DNA with ethanol. By 
comparing the DNA recovery (OD 260) to that of an 
identical aliquot treated similarly with the exception of 
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the addition of RNAse, the percent DNA of TNA was 
determined. 
Solution Hybridization 
The concentration of IGF-1 mRNA was measured using an 
labeled human IGF-1 (11) antisense cRNA and solution 
hybridization as described by Durnam and Palmiter (10), 
modified by Mathews et al. (12), and previously validated 
for bovine tissue (8). The human IGF-la probe used had a 
93% nucleotide homology with the bovine IGF-la cDNA (13). 
Briefly, the labeled hIGF-1 cRNA probe was hybridized to 
equal amounts of triplicated samples of TNA or RNA from 
each individual animal in 40 nl incubation buffer 
containing 0.6 M NaCl, 20 mM Tris'HCl (pH 7.5), 4 mM EDTA, 
0.1% SDS, 10 mM dithiothreitpl, 25% formamide, and 
approximately 1.8 x 10^ cpm labeled cRNA probe. After 
incubation overnight at 72 C, samples were treated with 40 
^g of ribonuclease A (Sigma Chemicals, St. Louis, MO) and 
250 units of ribonuclease T^ (Boehringer Mannheim, 
Indianapolis, IN) in the presence of 100 ng of herring 
sperm DNA in a total volume of 1 ml at 37 C for 45 min. 
Protected probe was precipitated by adding 100 pi of 6 M 
TCA, collected on #34 glass-fiber filters (Schleicher and 
Schuell, Keene, NH), and counted in a scintillation 
counter. The hybridization signal was compared with a 
standard curve generated with known amounts of a synthetic 
single stranded 664 bp hIGF-1 DNA. 
Statistical Analysis 
Growth hormone secretory peaks were determined by a 
mathematical model described previously (8). The acute 
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and chronic phases of the study were analyzed separately 
by analysis of variance of a 2 X 2 factorial design. Main 
effects of GH and Eg and treatment means were compared by 
F and least significant difference tests (14), 
respectively. Because of the dramatic response of liver 
IGF-1 mKNA to GH in the acute study, the natural 
logarithms of liver IGF-1 mRNA concentrations were 
analyzed. Correlations were calculated by using linear 
regression, and significance of correlation coefficients 
was determined by using the Fisher null hypothesis (14). 
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RESULTS 
Acute Response 
Acute response of plasma GH profiles, liver IGF-I 
mPNA concentrations, plasma IGF-1 concentrations, skeletal 
muscle IGF-1 mRNA concentrations, and plasma thyroid 
hormones to exogenous GH and/or E^are summarized in Table 
1. Injections of GH suppressed or masked all endogenous 
GH pulsatile activity. Therefore in analyzing the GH 
profiles of the steers receiving GH, the mean plasma GH 
concentration was considered to be the amplitude of one 
continuous peak. The baseline was not detectable during 
the first bleeding period. Steers receiving GH had 
approximately 17 fold greater (P<0.05) mean plasma GH 
concentrations and approximately 6.7 fold greater (P<0.05) 
amplitudes of GH peaks than control or Eg groups. There 
was no significant effect of Eg on mean plasma GH or any 
parameter of the GH profile. Steers given GH and GH+Eg 
had 6.0 (P<0.05) and 6.6 (P<0.05) fold greater liver IGF-1 
mRNA concentrations, respectively, than control steers, 
and 3.4 (P<0.05) and 3.7 (P<0.05) fold greater liver IGF-1 
mRNA concentrations, respectively, than steers given Eg. 
Steers given Eg had 1.8 (P<0.05) greater liver IGF-1 mRNA 
concentrations than the control steers. The Eg, GH, and 
GH+Eg steers had approximately 1.4 fold greater (P<0.05) 
plasma IGF-1 concentrations than control steers. There 
was no significant effect of GH or Eg on skeletal muscle 
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Table 1. Comparison of the acute response to exogenous GH 
and/or E2 on plasma GH profiles, plasma IGF-1, 
liver and skeletal muscle IGF-1 mRNA, and 
thyroid hormone concentrations of growing steers 
Item Control =2 GH GH+Eg SE* 
Mean plasma 
GH, ng/ml 4.7b 5.4b 92.3° 78.6° 10.0 
Mean GH peak 
amplitude, 
ng/ml 11.8^ 13.9b 92.3° 78.6° 10.3 
GH peak frequency, w 
# peaks/6 h 2.0 2.2^ 1.0° 1.0° 0.2 
GH baseline, 
ng/ml 2.9 3.1 n.m.® Had* 0.3 
Liver IGF-1 
mRNA, f 
amol/ug RNA^ 1.09b 1.92° 6.58* 7.15^ 0.121 
Plasma IGF-1, 
ng/ml 907^ 1216° 1245° 1239° 90.7 
Skeletal muscle 
IGF-1 mRNA,a 
amol/ug RNA? o.104 0.120 0.127 0.108 0.012 
Total T3, 
ng/ml 2.66 2.32 2.20 2.03 0.16 
Total T4, 
ng/ml 95.6 95.8 89.8 87.0 5.5 
^Standard error of mean. 
b,Cird^ean8 within a row without a common superscript 
differ (P<0.05). 
®Not measurable. 
fPercent RNA of TNA sample, control 72, E. 70, GH 73, 
GH+Eg 70. 2 
^Percent RNA of wet weight muscle tissue, control 
0.011, Eg 0.011, GH 0.012, GH+Eg 0.011. 
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mRNA concentrations, and plasma T3 and plasma T4 during 
the acute phase of the study. 
Chronic Response 
Chronic resonse of plasma GH profiles, liver IGF-1 
mRNA concentrations, plasma IGF-1 concentrations, skeletal 
muscle IGF-1 mRNA concentrations, and plasma 
concentrations of T3 and T4 to exogenous GH and/or Eg are 
summarized in Table 2. As observed during the acute 
response to GH administration, chronic treatment with GH 
suppressed all endogenous pulsatile activity, resulting in 
one sustained GH peak. Although the true amplitude of the 
GH peak occurred prior to the first blood sample, for 
statistical analysis the value used was an average of the 
concentration of GH in the first two samples. Baseline GH 
concentrations in the GH treated steers was obtained by 
averaging the last 6 samples (minutes 330 through 480). 
As shown in Figure 1, this described the baseline prior to 
the next GH injection. Steers receiving Eg implants had 
approximately 1.8 fold greater (P<0.05) mean plasma GH 
than control steers. Animals receiving GH had 
approximately 1.8 (P<0.05) and 3.0 fold (P<0.05) greater 
mean plasma GH levels than either the Eg implanted or 
control animals, respectively. The Eg treated steers had 
approximately 2 fold greater (P<0.05) amplitude of GH 
peaks than control steers. There were no differences in 
frequency of GH peaks or baseline concentrations between 
the Eg and control steers. 
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Table 2. Comparison of the chronic response to exogenous 
GH and/or E2 on the GH profiles, liver and 
skeletal muscle IGF-1 mRNA. plasma IGF-l, and 
thyroid hormone concentrations of growing steers 
Item Control E2 GH GH+Eg SE^ 
Mean plasma 
GH, ng/ml 5.lb 9.0° 16.2* 14.9* 1.2 
Mean GH peak 
amplitude, 
ng/ml 7.9b 16.3° 27.3* 27.8* 2.2 
3.2b 1.0° 1.0° 0.2 
GH baseline, 
ng/ml 3.2b 3.9b 11.7° 10.4° 0.7 
Liver IGF-1 
mRNA # f h è d c 
amol/ug RNA^ 1.32° 2.12° 3.38* 2.21° 0.161 
Plasma IGF-1, w h e e 
ng/ml 662® 844° 1792° 1559° 173.3 
Skeletal muscle 
IGF-1 m^A, _ vj -J vj_ J 
amol/ug RNA^ 0.108° 0.136°°0.112°°0.153° 0.0098 
Total T3, 
ng/ml 2.48 2.05 2.30 2.37 0.14 
Total T4, 
ng/ml 90.8 79.0 88.1 77.0 4.9 
^Standard error of mean. 
bfC,d,Qgans within a row without a common superscript 
differ (P<0.05). 
^Percent RNA of TNA sample, control 70, E. 68, GH 69, 
GH+Eg 70. 2 
^Percent RNA of wet weight muscle tissue, control 
0.010, Eg 0.012, GH 0.012, GH+Eg 0.013. 
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Steers given GH and GH+Eg had approximately 1.7 
(P<0.05) and 3.5 (P<0.05) fold greater amplitude of GH 
peak than Eg and control steers, respectively. Steers 
given GH and GH+Eg had significantly higher GH baselines 
(P<0.05) compared with control and Eg steers. Animals 
receiving GH had approximately 1.6 greater (P<0.05) 
concentrations of liver IGF-1 mRNA than animals receiving 
either GH+Eg or Eg, which had approximately 1.6 greater 
(P<0.05) concentrations of liver IGF-1 mRNA than control 
steers. There was a significant interaction (P<0.05) 
between GH and Eg on liver IGF-1 mRNA, as Eg significantly 
inhibited the IGF-1 mRNA response to GH in the liver. 
Steers given GH and GH+Eg had significantly greater 
(P<0.05) plasma IGF-1 concentrations than either control 
or Eg steers. Steers receiving GH+Eg had significantly 
greater (P<0.05) skeletal muscle IGF-1 mRNA concentrations 
than either GH or control steers. Steers receiving Eg had 
skeletal muscle IGF-1 mRNA concentrations which were 
significantly higher (P<0.05) than control steers. There 
was no significant treatment effect on plasma 
concentrations of T3 or T4. 
Correlation of Measurements 
Total and partial correlation coefficients for the 
relationship between liver IGF-1 mRNA, plasma IGF-1, 
skeletal muscle IGF-1 mRNA and plasma GH parameters in the 
chronic study (total includes data pooled from all 24 
animals and partial includes data from 12 animals given GH 
and C or 12 animals given Eg and GH+Eg) are summarized in 
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Table 3. There was a significant partial correlation 
between liver IGF-1 mRNA or plasma IGF-1 concentrations 
with mean plasma GH or amplitudes of GH peaks in GH and 
control animals. This relationship was absent in steers 
implanted with Eg. None of the correlations between 
muscle IGF-1 mRNA concentration and parameters of the GH 
profile or liver IGF-1 mRNA concentrations were 
significant. The correlation between liver IGF-1 mRNA and 
plasma IGF-1 was significant in GH and control steers, but 
not steers implanted with Eg. The correlation between 
plasma IGF-1 concentration and muscle IGF-1 mRNA 
concentration was significant in steers implanted with Eg, 
but not in GH and control steers. There was a negative 
relationship between plasma T4 and skeletal muscle IGF-I 
mRNA concentrations in (total correlation, r = -.38, 
p<.07) all animals in the chronic study. 
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Table 3. Total and partial correlation coefficients for 
the relationship between liver IGF-1 mRNA, 
plasma IGF-1, skeletal muscle IGF-1 mRNA and 
flasma 6H parameters In the chronic study (Total s data pooled from all 24 animals, GH/C and 
E/GH+E are partial regression coefficients, data 
pooled from either 12 animals In the GH and 
control or E2 and GH+E2 groups, respectively) 
Item Liver Plasma Muscle 
IGF-1 IGF-1 IGF-1 
mRNA mRNA 
Mean plasma GH, _ _ 
All animals .69* .65* .19 
GH and C .94® .73® .11 
Eg and GH+Eg .13 .51 .25 
GH peak amplitude, _ _ 
All animals .84® .57® .17 
GH and C .72® .77® .12 
Eg and GH+Eg .13 .33 .25 
Liver IGF-1 mRNA, _ 
All animals ... .49® .16 
GH and C ... .77® .15 
Eg and GH+Eg ... .18 .27 
Plasma IGF-1, _ 
All animals .49* ... .31 
GH and C .77® ... .19. 
Eg and GH+Eg .18 ... .67® 
®Probablllty (P<0.05) that correlation coefficient 
could not be arrived at with a pair of random, unrelated 
variables. 
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DISCUSSION 
The results of this study suggest that 6H and Eg 
stimulate growth of cattle through independent, although 
interactive, modes of action, and that IGF-1 acting in an 
autocrine/paracrine or endocrine manner can be of 
importance for growth, depending on hormonal environments. 
Chronic 6H treated steers had dramatically elevated liver 
IGF-1 mRNA concentrations and plasma IGF-1 concentrations, 
with no effect on skeletal muscle IGF-1 mRNA 
concentrations, suggesting an endocrine role for IGF-1. 
Steers given Eg or GH+Eg had elevated liver IGF-1 mRNA 
concentrations and significantly or slightly elevated 
plasma IGF-1 concentrations,, supporting the endocrine role 
of IGF-1, as well as increased skeletal muscle IGF-1 mRNA 
concentrations, supporting an autocrine/paracrine action 
of IGF-1. 
To our knowledge, this is the first report of Eg 
stimulating skeletal muscle IGF-1 mRNA. This was not 
unexpected, because skeletal muscle of cattle has been 
shown to contain Eg receptors (15), and the increase in 
IGF-1 mRNA in estrogen sensitive tissue is well documented 
(4,5,6). It is not clear if Eg acted to increase the 
response of skeletal muscle to GH, as the increase in 
muscle IGF-1 mRNA paralleled the increase in plasma GH 
observed here and in other studies with cattle (2,16) in 
response to long term exposure to Eg. However, this does 
not seem likely for two reasons; 1) the lack of 
correlation between mean plasma GH concentrations or 
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amplitude of GH peaks in the GH+Eg and Eg steers and 
skeletal muscle IGF-1 mRNA concentrations; and 2) the lack 
of response of muscle IGF-1 mRNA to GH+E2 during the acute 
phase of the study. The lack of an acute and chronic 
effect of GH treatment on skeletal muscle IGF-1 mRNA 
concentrations was not unexpected. While GH has been 
shown to increase IGF-1 mRNA concentrations in skeletal 
muscle of both intact and hypophysectomized rats (17,18), 
other studies have shown no response to GH of skeletal 
muscle IGF-1 mRNA or peptide in L6 myoblast cells (19), 
pituitary intact cattle (8,20), and pituitary intact pigs 
(21). 
The reason for the reduced response of liver IGF-1 
mRNA to GH during the chronic phase of the study in the 
steers given GH+Eg is unknown. This been reported in 
ovariectomized, hypophysectomized rats (4), where chronic 
treatment with 0.1 ug Eg/day along with 10 or 90 ug 
hGH/day increased uterine and lowered hepatic IGF-1 mRNA 
expression, compared with rats receiving GH alone. There 
were no significant differences in plasma IGF-1 
concentrations. The authors suggested that the antagonism 
of GH stimulated hepatic IGF-1 mRNA by Eg could account 
for the catabolic effect of Eg in the rat. This 
explanation is questionable because this antagonism has 
now been observed in a species in which Eg is anabolic. 
We observed the same inhibition in chronic treated GH+Eg 
steers which had elevated plasma IGF-1 and skeletal muscle 
IGF-1 mRNA, not in steers which just had elevated plasma 
IGF-1 (acute GH, acute GH+Eg, chronic GH) or skeletal 
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muscle IGF-1 mRNA concentrations (chronic Eg). This 
suggests elevation of both plasma IGF-1 and skeletal 
muscle (nonhepatic) IGF-1 mRNA concentrations are 
important for this antagonism to occur. 
While both elevated plasma IGF-1 and nonhepatic IGF-1 
synthesis appear important for suppression of hepatic IGF-
1 synthesis in response to GH, it is not clear why there 
is a discordance between liver IGF-1 mRNA expression and 
plasma IGF-1 concentrations in the chronic Eg, GH, and 
GH+Eg treated steers, since the liver is reported to be 
the primary contributor of IGF-1 to plasma (22). This 
discordance could be explained by lowered metabolic 
clearance of IGF-1 in the GH+Eg steers due to greater 
production of the GH dependent IGF-1 binding proteins 
(IGF-IBP) (23), or it could be due to nonhepatic 
contributions plasma IGF-1. It has been postulated that 
the association between circulating IGF-1 and GH 
concentrations is more related to the GH dependence of the 
binding protein, than to the effects of GH on IGF-1 
production (23). This could explain the same plasma IGF-1 
concentrations in the GH and GH+Eg steers, although they 
had different liver IGF-1 mRNA concentrations. These 
animals may have had a certain concentration of IGF-IBP 
which were saturated by either hepatic or nonhepatic 
derived IGF-1. The contribution of IGF-1 produced by 
skeletal muscle or other Eg target organs to plasma IGF-l 
in this study is not known. However, the partial 
correlation between skeletal muscle IGF-1 mRNA 
concentrations and plasma IGF-1 in the chronic Eg steers 
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was significant, while the relationship between liver I6F-
1 nRNA and plasma IGF-1 was lost. This suggests that 
under certain conditions non-hepatic tissues might 
contribute to plasma IGF-1. Kidney, seminal vesicles, and 
bulbo-urethrals (24) in addition to skeletal muscle, have 
been shown to increase in size in response to Eg treatment 
in sheep. These could also contribute to plasma IGF-1. 
The direct stimulation of liver IGF-1 mRNA by Eg 
during the acute phase of the study, independent of an 
increase in plasma GH, was unexpected. Brier et al. (25) 
have shown that Eg increased hepatic GH binding in cattle, 
primarily due to an increase in receptor concentration. 
The livers of Eg treated steers may be more sensitive than 
those of control steers. Studies in rats have shown no 
effect of acute Eg on hepatic IGF-1 mRNA concentrations 
(4). This could be explained in part by a species effect, 
or because the rats were hypophysectomized. In the 
absence of GH, any Eg stimulation of hepatic GH binding 
would not have an effect. 
It has been proposed that the mode of action of 
exogenous estrogen on growth of cattle was mediated 
through stimulation of the pituitary GH/hepatic IGF-1 axis 
(1). The results of this study suggest that although Eg 
does stimulate increases in both plasma GH and liver IGF-l 
mRNA concentrations, its stimulation of IGF-1 mRNA 
concentrations in skeletal muscle appears to also be of 
physiological significance in steers. The stimulation of 
IGF-1 synthesis in skeletal muscle by Eg could explain in 
part why exogenous GH and Eg stimulate growth to an 
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equivalent degree, even though plasma IGF-1 concentrations 
are significantly higher in GH treated animals, or why a 
combination of GH and Eg can stimulate growth beyond that 
observed with either GH or Eg alone, with no further 
Increases in plasma GH or IGF-1 (3). 
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ABSTRACT 
Steers were made hyper- or hypothyroid to study the 
effects of physiological alterations in thyroid hormone 
status on plasma 6H profiles, plasma IGF-1 concentrations, 
and relative abundance of skeletal muscle and liver IGF-1 
mRNA in cattle. Eighteen yearling crossbred steers (360 
to 420 kg) were randomly allotted to hyperthyroid (so 
injection 0.6 ug/kg BW L-thyroxine for 10 days), 
hypothyroid (oral thiouracil; 0.25% diet plus 12.5 g 
capsule/day for 17 days) or control (sc injection buffer) 
treatment groups. Blood samples were taken for 
measurement of GH, IGF-1, T4 and T3 by RIA. Samples of 
liver and skeletal muscle were taken by biopsy for 
measurement of IGF-1 mRNA by.solution hybridization. 
Steers receiving thiouracil had 57 and 53% (P<.05) lower 
T4 and T3, respectively, than the control steers (84.1 and 
1.7 ng/ml). The hyperthyroid steers had 228 and 65% 
greater (P<.05) T4 and T3 than control steers. Neither 
treatment had any significant effects on plasma GH 
profiles, liver IGF-1 mRNA, or plasma concentration of 
IGF-1. There was a trend, however, for the hyperthyroid 
group to have suppressed liver IGF-1 mRNA and plasma IGF-1 
concentrations. There was no effect of thyroid hormone 
alteration on skeletal muscle IGF-1 mRNA concentrations. 
The results of this study suggest that short-term changes 
in thyroid status of cattle had no major impact on the GH-
IGF-1 axis or skeletal muscle IGF-1 mRNA. 
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INTRODUCTION 
Because growth of cattle is related to plasma 
concentrations of insulin-like growth factor-1 (I6F-1) (1-
3), knowledge of factors regulating the growth factor is 
important. Plasma IGF-1 concentrations are under partial 
control by growth hormone (GH), but nutrition (1) as well 
as other hormones play a role in regulation of the 
hypothalamus-pituitary-IGF-1 axis. Bulls have higher 
concentrations of plasma IGF-1 than steers (3,4) or 
heifers (3). Exogenous estradiol has been reported to 
increase plasma IGF-1 in steers (2,5). Because thyroid 
hormones are involved in the regulation of the GH gene (6) 
and may have an effect on binding of GH to hepatocytes 
(7), they have been implicated in regulation of IGF-l 
production (8,9). Based upon these studies with cell 
cultures and laboratory animals, it seemed possible that a 
change in thyroid status could impact one or more segments 
of the pituitary-GH-IGF-1 axis in growing animals. In 
another study (2), we observed a negative relationship of 
thyroid hormone concentrations in plasma and concentration 
of IGF-1 mRNA in skeletal muscle, suggesting that higher 
concentrations of thyroid hormones might restrict local 
production of growth factors in tissues. Therefore the 
objectives of this study were to determine the effects of 
altering thyroid hormone status of cattle on plasma GH 
profiles, plasma IGF-1, and IGF-1 mRNA in liver and 
skeletal muscle. 
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MATERIALS AND METHODS 
Animals 
Eighteen crossbred steers approximately 13 months of 
age and weighing between 363 and 424 kg were randomly 
allotted to three treatment groups. The animals were 
housed in an open lot and had access to an open front 
shed. They were group fed ad libitum twice daily a diet 
containing 79% cracked corn, 12% ground cobs, 4% molasses, 
and 5% supplement. The animals had ad libitum access to 
water. The experiment was conducted in July-August. 
Hormone Treatments 
Starting on day 1 of the experiment six steers were 
fed the diet supplemented with 0.2 % (w/w) thiouracil 
(Sigma). Beginning on day 12 and continuing through day 
17 each animal received an additional 12.5 g/d of 
thiouracil in a gelatin capsule, administered orally. On 
days 8 through 17, six steers received a daily 
subcutaneous (sc) injection of 0.6 ug L-thyroxine 
(Sigma)/kg body weight dissolved in 0.9 % NaCl, pH 12. 
Six steers served as controls and received sc injections 
of 0.9 % NaCl. 
Tissue Sampling 
On day 16, indwelling catheters (Tygon microbore 
tubing, 0.02 mm i.d. x 0.066 mm d.d.. Fisher Scientific, 
Pittsburgh, PA) were inserted into the jugular vein and 
held in place with elastic tape (Elastikon, Jonson and 
Johnson, New Brunswick, NJ). The catheters were kept 
patent overnight by filling with sterile physiological 
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saline containing 100 u heparin/ ml. The following day 
the animals were moved into an enclosed shelter and 
loosely restrained by haltering in individual stalls. 
Serial blood samples (10 ml) were collected into 25 ul of 
sterile saline containing 5000 u heparin/ml at 15 minute 
intervals for 8 hours, from 0800 to 1600. Blood samples 
were immediately centrifuged and plasma was stored at -20 
C until analysis for GH, IGF-1, thyroxine (T4), and 
tiiodothyronine (T3). 
Liver and muscle samples were obtained by biopsy 
immediately following collection of the blood samples. 
The samples were taken from conscious animals restrained 
in a squeeze chute. Small areas between the eleventh and 
twelfth ribs and over the semimembranosus muscle were 
shaved, disinfected with Pharmadine (Sherwood 
Pharmaceuticals Company, Mahwah, NJ), and wiped clean with 
gauze soaked in 0.8% (v/v distilled water) Zephiran 
Chloride (17% alkylbenzyldimethylammonium chlorides; 
Winthorp Laboratories, New York, NY). Injection of 
Xylocaine (2% Lidocaine Hydrochloride; Astra 
Pharmaceutical Products, Westborough, MA) was used as 
local anesthetic, 6 ml given in the skin and intercoastal 
muscle and 15 ml given subcutaneously and in the 
semimembranosus muscle. After 5 minutes, an incision 
approximately 1.3 cm in length was made between the 
eleventh and twelfth ribs. The cannula (0.8 id x 31 cm) 
and trocar machined to fit inside the cannula were 
modified from the description by Hughes (10) and made at 
the Iowa State University Engineering Research Institute 
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Machine Shop. The trocar and cannula, kept sterile by 
storing in 0.8% Zephiran Chloride, were inserted through 
the incision. The liver was located using the trocar as a 
probe and a biopsy obtained by turning the canula into the 
liver with even pressure. After removal, the liver sample 
was placed in a sterile bag, immediately frozen on dry 
ice, and stored at - 70 until further use. After 15 
minutes, a 5 cm incision was made to expose the 
semimembranosus. A stainless steel canula (1.0 id x 11 
cm), sharpened at one end, was kept sterile by storing in 
0.8% Zephiran Chloride. After turning the cannula into 
the muscle, a vacuum was applied with a hypodermic syringe 
and the muscle biopsy was removed, placed in a sterile 
bag, immediately frozen on dry ice, and stored at - 70 C 
until further use. The incisions were cleaned with 
sterile gauze and closed with disposable skin staples (3M 
Medical Division, St. Paul, MN). The areas were covered 
with Furacin (0.2% Furacin; Norden Laboratories, Lincoln, 
NE) and the animals given an intramuscular injection of 
Combiotic (penicillin and dihydrostreptomycin, Pfizer, 
Inc. NY). 
Radioimmunoassays 
Plasma 6H and IGF-1 concentrations were determined 
using double-antibody radioimmunoassay (RIA) techniques 
described previously (3). Concentrations of total plasma 
T4 and total T3 were measured using commercial 
radioimmunoassay kits (Diagnostic Products Corporation, 
Los Angeles, CA 90045) as described (3). 
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Nucleic Acid Isolation 
Samples of RNA and total nucleic acids (TNA) were 
isolated from each tissue sample by using the guanidium 
isocythiocyanate-cesium cloride method and sodium dodecyl 
sulfate-proteinase K digestion, phenol/chloroform method, 
respectively, as described previously (3). Concentrations 
of TNA and RNA were determined spectrophotometrically by 
measuring O.D. at 260 nm. The integrity and concentration 
of RNA was verified using agarose gel electrophoresis. 
The amount of DNA in each TNA sample was determined 
fluorometrically by the method of Labarca and Paigen (11). 
Solution Hybridization 
I6F-1 mRNA was measured by solution hybridization as 
described by Durnam and Palmiter (12), modified by Mathews 
et al. (13), and validated for bovine tissue (3). 
Briefly, a labeled human IGF-1 antisense cRNA probe 
was hybridized to equal amounts of triplicated TNA or RNA 
samples from each individual animal in 40 /il incubation 
buffer containing 0.6 M NaCl, 20 mM Tris'HCl (pH 7.5), 4 
mM EDTA, 0.1% SDS, 10 mM dithiothreitol, 25% formamide, 
and approximately 1.8 x 10^ cpm labeled cRNA probe. After 
an overnight incubation at 72 C, samples were treated with 
40 fig of ribonuclease A (Sigma Chemicals, St. Louis, MO) 
and 250 units of ribonuclease T^ (Boehringer Mannheim, 
Indianapolis, IN) in the presence of 100 ftg of herring 
sperm DNA in a total volume of 1 ml at 37 C for 45 min. 
Protected probe was precipitated by using 100 pi of 6 M 
TCA, collected on #34 glass-fiber filters (Schleicher and 
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Schuell, Keene, NH) and counted in a scintillation 
counter. The hybridization signal was compared with a 
standard curve of known amounts of a synthetic single 
stranded 664 bp hIGF-1 DNA, which was synthesized from the 
pGEM 3Z(+) plasmid (13). 
Statistical Analysis 
Growth hormone secretory peaks were determined by a 
mathematical model described previously (3). Overall 
effects of thyroid hormone status were analyzed as a 
completely random design by using analysis of variance 
followed by F and least significant difference tests (14). 
Correlation coefficients were calculated by using linear 
regression, and significance of correlation coefficients 
was determined by using the fisher null hypothesis (14). 
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RESULTS 
The effects of administering thiouracil and T4 on 
concentrations of thyroid hormones, 6H, and lGF-1 in 
plasma and IGF-1 mRNA in muscle and liver are shown in 
Table 1. Steers receiving thiouracil had 2.0 (P<0.05) and 
2.1 (P<0.05) fold lower plasma T4 and T3 than control 
animals. Animals injected with T4 had 2.3 (p<0.05) and 
1.6 (P<0.05) fold greater concentrations of T4 and T3 than 
control steers. The thiouracil and thyroxine treatments 
had no statistically significant effect on any parameter 
of the GH profile or liver IGF-1 mRNA concentrations in 
liver and muscle. There were trends, however, which may 
be of physiological importance. Both treatments tended to 
depress plasma concentrations of GH and IGF-1. The 
decrease in mean plasma GH seemed to result from changes 
in different parameters of the GH profile. Steers given 
thiouracil had approximately 24% lower plasma baseline 
concentrations of GH compared with the control group, 
whereas steers given thyroxine had 39% lower amplitude of 
GH peaks. Increasing thyroid hormones with injections of 
T4 reduced liver IGF-1 mRNA 30% and plasma IGF-1 
concentrations 26% in comparison with control steers. 
Reducing thyroid hormones with thiouracil had no effect on 
liver IGF-1 mRNA or plasma IGF-1. There were no 
significant differences in concentrations of lGF-1 mRNA in 
skeletal muscle among the three groups of steers. There 
were no relationships between plasma T4 or T3 
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Table 1. Total T4, total T3, plasma GH profiles, and IGF-
1 status of steers receiving daily treatments of 
either 25g thiouracil (hypothyroid), a sc 
injection of 0.6 ug/Kg body weight L-thyroxine 
(hyperthyroid), or no treatment (control) for 14 
days 
Parameter Hypothyroid Hyperthyroid Control SE® 
Plasma T4, ng/ml 42.0^ 191.7° 84.1* 8.0 
Plasma T3, ng/ml 0.79b 2.78° 1.68* 0.3 
Mean plasma GH, 
ng/ml 2.6 2.7 3.3 0.3 
Mean GH peak amplitude, 
ng/ml 6.7 4.0 6.6 1.4 
GH peak frequency 
1 peaks/8h ' 2.0 2.0 3.2 0.5 
Mean GH baseline, 
ng/ml 1.9 2.3 2.5 0.2 
Mean plasma IGF-1 
ng/ml '415 336 456 60 
Liver IGF-1 mRNA, 
amol/ug RNA 2.87 1.98 2.82 0.39 
Skeletal muscle 
IGF-1 mRNA,. 
amol/ug RNA 0.24 0.20 0.20 0.03 
^Standard error of mean. 
^^'^Means within a row without a common superscript 
differ (P<0.05) concentrations and any parameter of the GH 
profile, plasma IGF-1, or IGF-1 mRNA in liver and muscle. 
^Percent RNA of wet weight tissue, hyper 0.0073, 
hypo 0.0070, control 0.0072. 
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DISCUSSION 
It Is well known that thyroid hormones increase GH 
secretion in rats devoid of thyroid hormones (8), 
presumably because of reduced expression of the GH gene in 
the pituitary (6). Comparable studies have not been done 
with cattle. Reducing T4 and T3 to 50% of control 
concentrations for 18 days tended to reduce plasma 
concentrations of GH, but none of the parameters of the GH 
profile were significantly changed. Increasing T4 and T3 
by daily injections of T4 for 10 days also tended to 
decrease concentrations of GH in the plasma, but not 
significantly. These results suggest that altering the 
thyroid status of steers outside of the expected range of 
plasma concentrations does not substantially affect GH 
secretion. 
Even though the relative decline of 20% in plasma GH 
may seem to be of physiological significance, there were 
no effects of alteration of thyroid status on liver IGF-1 
mRNA or plasma concentrations of IGF-1. In the Snell 
dwarf mouse, injections of GH or T4 increased weight gain 
in a dose dependent manner (15). Plasma somatomedin-like 
activity was also increased by each hormone, but not in 
relation to dose. In hypophysectomized rats, T3 did not 
increase IGF-1 production by the liver or concentration in 
plasma in the absence of GH (9). There was some response 
to T3 when given with GH. The greatest response to T3 
occurred when given with GH and Cortisol. Adequate 
studies have not been done to determine the minimal 
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quantity of thyroid hormones needed for production of IGF-
1 by the liver. Seemingly the concentration of thyroid 
hormones can be significantly reduced in cattle without 
affecting their hepatic I6F-1 status. We would also 
conclude that cattle have adequate thyroid hormones to 
maintain liver production of I6F-1. 
The results of earlier experiments indicating a 
negative relationship between plasma concentrations of 
thyroid hormones and IGF-1 mRNA in skeletal muscle (3) 
suggested that cattle might benefit from some reduction in 
thyroid activity. Decreasing thyroid activity by feeding 
of thiouracil, however, did not change abundance of IGF-I 
mRNA in the semimembranosus muscle. Likewise increasing 
the thyroid status of these cattle with injections of T4 
did not affect level of the message in muscle. Presumably 
production of IGF-1 in muscle was not affected, thereby 
eliminating a possible action of thyroid hormones on local 
production of the growth factor. 
It is not known what the response would have been 
with greater changes in thyroid status or subjecting the 
animals to change over a longer period of time. The 
concentrations of T4 and T3 achieved in this study were 
definitely outside of the range of concentrations reported 
for cattle (16-18). Studies with rats have shown that the 
effects of severe hypothyroidism on GH and somatomedin-
like activity occurs within 14 days (8) and the response 
to injected T3 occurs within 3 (9) days. Significant 
increases in concentrations of T4 and T3 in plasma of 
steers occurred with one day of refeeding (19). 
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The relationship of thyroid status with growth of 
cattle is conflicting. Positive as well as negative 
correlations have been reported (18). Growth of sheep has 
been found to be adversely affected by thyroid activities 
considerably above or below the optimum (20). Though not 
statistically significant, our observations on plasma GH 
and IGF-1 support the concept that the euthyroid state may 
be optimum for growth of cattle. Implanting estrogen + 
progesterone in steers has been shown to increase weight 
gain and plasma concentrations of T4 (17). Restricting 
energy intake of steers has been reported to reduce weight 
gain and plasma T3 and T4 (19). It was suggested that 
these alterations in thyroid hormones might have been 
invoved in the changes in growth. Based upon the results 
of our study, it seems unlikely that these changes in 
thyroid hormones affected growth by means of liver or 
muscle IGF-1. 
The results of this study suggest that short-term 
physiological changes in thyroid status have no major 
impact on the pituitary-GH-hepatic IGF-1 axis or skeletal 
muscle IGF-1 mRNA in growing cattle. 
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GENERAL DISCUSSION 
The observations reported in this dissertation 
support two major conclusions: 1) both endocrine and 
autocrine/paracrine properties of IGF-1 can contribute to 
growth in pituitary intact cattle and 2) the importance of 
extending currently available recombinant DNA techniques 
to pituitary intact, whole animal studies. 
There has been much debate over the importance of 
plasma IGF-1 (endocrine acting IGF-1) versus target tissue 
derived IGF-1 (autocrine/paracrine acting IGF-1). The 
results of studies in this dissertation suggest that under 
normal physiological conditions, as well as in situations 
where exogenous GH is adminstered, endocrine IGF-1 is 
important. In Section I, the range in variation of 
endogenous plasma GH typically found in cattle of 
different sexes, specifically peak concentrations, were 
related to concentration of IGF-1 mRNA in liver and IGF-1 
in plasma. In Section II, injections of GH resulting in 
one large, sustained peak dramatically stimulated liver 
IGF-1 mRNA expression and plasma IGF-1 concentrations. 
Therefore the endocrine mode of IGF-1 seems to be 
dependent on amplitude of GH peaks occurring naturlly or 
induced with exogenous GH. The lack of importance of 
autocrine/paracrine acting IGF-1 in these hormonal 
conditions, as indicated by the lack of effect of both 
physiological and exogenous GH on skeletal muscle IGF-1 
mRNA concentrations, is not surprising. To my knowledge, 
the presence of GH receptors skeletal muscle of cattle has 
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not been demonstrated. Studies in rats have shown 
expression of the skeletal muscle GH receptor gene (l), 
but not a functional receptor. 
Under specific hormonal environments, such as with 
exogenous Eg, conditions exist where autocrine/paracrine 
acting I6F-1 is important. This was demonstrated in 
Section II of this dissertation, where skeletal muscle 
IGF-1 mRNA was increased by Eg, and in other studies where 
IGF-1 mRNA and growth was stimulated in different target 
tissues by Eg (2,3,4). It is not known if Eg's effect on 
skeletal muscle IGF-1 synthesis was direct. Section III 
demonstrated that it was not mediated through alteration 
of plasma thyroid hormones. This had been suggested as a 
possible mechansism through which Eg stimulates muscle 
growth. Eg increases the number of liver GH receptors 
(5). If there are no functional GH receptors in skeletal 
muscle. Eg may stimulate expression of IGF-1 mRNA 
differently in skeletal muscle than in liver. This could 
explain why during the acute phase of the study reported 
in Section II, the effects of Eg on concentrations of IGF-
1 mRNA were evident in liver but not in skeletal muscle. 
It is possible Eg*s effects on concentrations of IGF-1 
mRNA in skeletal muscle is mediated through production of 
an "estromedin", a local growth factor produced in 
response to Eg stimulation. 
The importance of physiological variation of Eg 
concentrations in plasma for stimulation skeletal muscle 
IGF-1 synthesis and growth of mature cattle is not clear. 
Section I demonstrated that concentrations of skeletal 
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muscle IGF-1 mRNA of bulls, steers, and heifers seemed to 
be sensitive to reported concentrations of total estrogens 
(bulls > heifers > steers) (6). Although the low 
concentrations of IGF-1 mRNA in skeletal muscle could 
explain why the growth response of steers to Eg is greater 
than bulls or heifers (7), normal growth of these animals 
can not be explained by estrogen stimulated muscle IGF-1 
production. Confounding these observations is the 
presence of testosterone (T) in bulls. T increases the 
sensitivity of satellite cells to IGF-1 (8). Therefore, 
IGF-1 produced in skeletal muscle of bulls could be more 
potent for growth than IGF-1 produced in muscle of steers 
or heifers. A period in development when physiological 
variations of Eg and T are khown to be important is 
puberty. Pubertal surges of plasma IGF-1 which are 
associated with increased growth have been demonstrated in 
man, baboon, rodents, and cattle (6,9-11). It is not 
clear if this increased growth is mediated through GH 
stimulated plasma IGF-1, or local IGF-1 production. It is 
attractive to postulate that both are important and the 
surge in growth associated with puberty can be explained 
by three main mechanisms: 1) a surge in concentrations of 
plasma Eg acts to increase nonhepatic IGF-1 production, 2) 
Eg increases concentrations of plasma GH and IGF-1 and 3) 
the potency of endocrine (plasma) and autocrine (produced 
locally) acting IGF-1 is enhanced by an increase in plasma 
concentrations of T in intact males. 
Regardless of the origin of IGF-1, synthesized 
locally or plasma derived, the question remains as to how 
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IGF-1 stimulates growth of skeletal muscle. There are two 
phases of postnatal muscle growth in cattle (12). The 
first phase of growth is a combination of increasing 
cellularity (number of nuclei/muscle fiber) and an 
increase in cell size (protein/DNA ratio). This occurs 
between the ages of 4 and 13 months (110 to 360 kg) in 
cattle. The increasing cellularity is a result of nuclei 
being added to a muscle fiber by mitosis of satellite 
cells and their fusion into a fiber. The second phase 
occurring after 13 months, is primarily limited to an 
increase in cell size due to increased protein deposition. 
The cattle used in the studies in this dissertation would 
have been reaching the end of the first phase, and 
entering the second phase. ^Therefore, it is not clear if 
lGF-1 may have been stimulating satellite cell division 
and differentiation, increasing protein deposition in 
mature muscle fibers, or both. Does locally produced IGF-
1 in response to Eg act differently than plasma derived 
IGF-1? iQ situ hybridization and antibody localization 
studies need to be performed to determine where IGF-1 and 
its receptor are being produced and acting in muscle 
tissue in response to Eg. 
The significance of IGF-1 mRNA expression in non-
hepatic tissue, under conditions where plasma IGF-1 
appears to be important for growth, is not clear. 
However, this demonstrates the importance of the second 
conclusion, using pituitary intact animals for growth 
studies. Most of the studies demonstrating the GH 
dependancy of IGF-1 mRNA expression in nonhepatic tissues 
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have been performed in hypophysectomized animals. Other 
studies have shown hormones stimulate transcription of 
specific genes in cells grown in culture. While these 
studies are important in their own right, they are not an 
end to themselves. The question arises as to which is the 
more important observation, the specific hormonal 
stimulation of gene expression in an hypophysectomized 
animal model or selected cell line completely devoid of 
any other pituitary and/or pituitary dependent hormones, 
or the observation that the specific hormone has no effect 
on the expression of the same gene in a pituitary intact 
animal. For example, 6H stimulates I6F-1 gene expression 
in skeletal muscle of hypophysectomized rats (13). 
However, as reported in Section II of this dissertation, 
GH had no effect on skeletal muscle IGF-1 mRNA expression 
in pituitary intact cattle. In another example, T3 has 
been shown to stimulate GH gene transcription in pituitary 
cells in culture (14). However, as demonstrated in 
Section III of this dissertation, elevating thyroid 
hormone concentrations did not increase plasma GH 
concentrations above that observed in euthyroid control 
animals. 
Obviously, the observations obtained from 
hypophysectomized rats or cell culture, and pituitary 
intact animals, are of equal importance. Unfortunately, 
the majority of endocrinologists do not feel this way. 
Their argument is that observations from pituitary intact 
animals are obtained from a poorly controlled experiment, 
or that not observing a relationship between hormone and 
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gene was due to proceedural wrongdoings. However, this is 
not to say that scientists who study whole animal models 
are not without their prejudices. Many of these 
scientists are too concerned with statistical 
significance, ignoring possible physiological 
significances. Regardless, there is an important gap 
which needs to be narrowed between the "molecular 
biologists" and the whole animal 
physiologists/endocrinologists. Hopefully, the gap will 
be lessened with the development and widespread use of 
combined molecular biological and whole animal techniques, 
such as transgenic animals. In these studies, gene 
regulation in animals with physiological concentrations of 
pituitary hormones and pituitary hormone dependent growth 
factors, can be studied. 
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APPENDIX. SOLUTION HYBRIDIZATION PROTOCOL 
Nucleic Acid Isolation 
Place 200 mg of frozen liver into a 50 ml blue-top 
tube. Add 5 ml proteinase K solution (PK) and immediately 
homogenize for 7-10 seconds at speed 6 on a polytron. 
Let set for approximately 5 minutes so foam settles. 
Incubate for 30 minutes at 68 C. After incubation, 
transfer PK into a clean and sterilized 15 ml glass Corex 
tube. Add 2.5 ml of chloroform and 2.5 ml of HgO 
saturated phenol and mix thoroughly. Spin in Beckman JA-
20 at 10000 rpm for 15 minutes. This is a very important 
step for obtaining clean TNA preparations, as 
centrifugation must be fast enough to precipitate 
denatured, digested protein. After centrifugation, 
transfer upper aqueous layer to a new clean Corex tube. 
Add 5 ml of chloroform, mix well, centrifuge again for 15 
minutes. Transfer upper layer to another Corex tube and 
perform a second chloroform extraction and centrifugation. 
After second chloroform extraction, the aqueous organic 
interphase should be clear. If not clear at this point, 
then a clean TNA preparation will be difficult to obtain. 
A "cloud^like, fluffy" interphase at this stage is 
indicative of old phenol and/or insufficient 
centrifugation speed. If upper aqueous layer is clean 
after second chloroform extraction it can be ethanol 
precipitated by transferring to a polypropylene tube, 
adding two volumes of 95% ethanol and incubating in - 20 C 
freezer overnight. Following overnight incubation, tubes 
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can be centrifugea at lOOOO rpm in JA 20. Resuspend TNA 
pellet in bottom of tube in ddHgO. This step may require 
heating (68 C). Once TNA is dissolved in HgO, add 2% v/v 
lOX SET buffer. Add 5 ul of TNA mixture to 695 ul of HgO 
and measure OD at 260 for quantification (OD 260 * 7.0 = 
ug TNA / ul TNA solution). Store TNA at - 20 C until use 
in solution hybridization. 
For muscle RNA isolation, place 500 mg of frozen 
muscle into a 50 ml blue-top tube. Add 16 ml of ice-cold 
GIT (4M guanidine thiocyanate, 25 mM sodium acetate pH 
6.0, 0.835 % /9-mercaptoethanol v/v) solution and 
homogenize for 15 seconds at speed 6 on polytron. Keep 
tubes on ice until they are centrifuged. Layer homogenate 
carefully onto 4 ml of CsCl (5.7 M CsCl, 0.05 M sodium 
acetate pH 6.0) in an ultracentrifuge tube. Spin in 
ultracentrifuge at 32000 rpm for 21 h at 20 C. After 
centrifugation, carefully aspirate off top GIT layer and 
all but 200 ul of the bottom CsCl layer. Cut 
ultracentrifuge tube with a clean razor blade 
approximately 1.0 cm from bottom. Remove remaining CsCl 
from bottom of tube with a pipetteman. Add 200 ul of 
ddHgO and resuspend pellet, transferring it to an 
autoclaved mlcrofuge tube. Rinse ultracentrifuge tube 
bottom with 100 ul of ddHgO and add to mlcrofuge tube. 
AIWAYS USE FRESH PIPETTEMAN TIPS-KEEP ddH^O STOCK CLEAN. 
Add 5 ul RNA solution to 695 ul HgO and measure OD at 260 
(OD 260 * 5.6 = ug RNA / ul solution). Store RNA in ddHgO 
at - 70 C. Before use in solution hybridization, check 
integrity by running a 1 ug aliquot on an agarose gel. 
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Solution Hybridization 
Add 20 ul of concentrated hybridization solution 
hybridization mix to 20 ul of single stranded standard or 
TNA/RNA sample. Samples and standards should be run in 
triplicate, and for best results all samples should be 
assayed at equivalent concentrations (10 ug liver TNA and 
25 ug muscle RNA). Be sure to include blanks (0 standard 
or nucleic acids) and total count tubes in each assay. 
Mix well and spin briefly in a microfuge tube. Layer two 
drops of mineral oil (prevents evaporation) on top of mix 
and microfuge again. Incubate at 72 C overnight. 
Following overnight incubation, let samples cool for 15 
minutes. Add 1 ml of ribonuclease buffer to each tube an 
vortex well to disperse mineral oil and incubate for 45 
minutes at 37 C. Following incubation, add 100 ul of 100 
% TCA. Vortex and incubate on ice for one hour. Place 
sample onto TCA-PPi ( 3% TCA, 1% sodium pyrophosphate) 
wetted, glass fiber filter. Wash tube with TCA-PPi and 
ethanol. Count filter in scintilation counter (2 minutes 
for liver samples, 10 minutes for muscle samples). 
Buffers 
Concentrated hybridization mix 1 ml 
Formamide 
SDS 
DTT 
cRNA 
HgO 
NaCl (5M) 
EDTA I .5M) 
Tris r2M, pH 7.5) 
240 ul 
16 ul 
20 Ul 
500 Ul 
10 Ul 
200 ul R 
7.5 X 10^ cpm 
volume 
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Proteinase K solution lOO ml 
Proteinase K (10 mg/ml) 2 ml 
lOX SET 10 ml 
NaCl (5M) 2 ml 
HgO 86 ml 
Ribonuclease buffer 50 ml 
lOX RNAse salts 5 ml 
Herring sperm DNA (2.0 ug/ml) 2.5 ml 
H-O 42.5 ml 
Ribonuclease A (10 ug/ml) 200 ul 
Ribonuclease T1 (500,000 u/ml) 25 ul 
lOX RNAse salts 
NaCl 
Trls 
EDTA 
HzO 
5M) 
2M, pH 7.5) 
.5M) 
100 ml 
60 ml 
5 ml 
10 ml 
25 ml 
